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Introduction {#sec005}
============

*BRCA1/2*-associated breast cancers account for about 25--30% of familial breast cancers, and for about 3% of all breast cancers \[[@pone.0120189.ref001]\]. *BRCA1*-associated breast cancers differ from tumours not associated with *BRCA* mutations with respect to pathological features, e.g. they are more often estrogen receptor negative and high grade and have a higher frequency of somatic abnormalities in prognostically important genes such as *P53* \[[@pone.0120189.ref002],[@pone.0120189.ref003]\]. The biological background of *BRCA1/2* \[[@pone.0120189.ref004]\] and different pathological aspects of *BRCA1*-associated tumours support the hypothesis that patients carrying a *BRCA1* and/or *BRCA2* mutation might have a worse breast cancer prognosis compared to non-carriers.

An impressive number of studies have already been conducted to address the association between *BRCA1* and/or *BRCA2* mutation carriership and breast cancer survival ([Table 1](#pone.0120189.t001){ref-type="table"} and [Table 2](#pone.0120189.t002){ref-type="table"}). Study results were inconsistent, possibly due to differences in study design, study size, study populations and methodological rigor. Yet, accurate estimation of the effect of carriership, independent of tumour characteristics, on breast cancer survival is needed to optimize treatment choices and surveillance policies for *BRCA* mutation carriers with breast cancer.

10.1371/journal.pone.0120189.t001

###### Characteristics and quality scores of studies included in the review (N = 66).

![](pone.0120189.t001){#pone.0120189.t001g}

  Author + year           Country                  Study type                                                        Types of patients included                           'Non-carrier group' tested   Carriers/ 'non-carriers' matched?   Factors matched   Diagnose years of breast cancer (incl period)   N of carriers   N of 'non-carriers'    Quality score                               Selection + Misclass bias                   All biases together                                                           
  ----------------------- ------------------------ ----------------------------------------------------------------- ---------------------------------------------------- ---------------------------- ----------------------------------- ----------------- ----------------------------------------------- --------------- ---------------------- ------------------------------------------- ------------------------------------------- --------------------- ------- ------- ------- ------- ------- ------- ------- ------
  Ansquer, 1998           France                   Unselected cohort                                                 age diagnosis \< 36                                  Yes                          NA                                                                                                                    1/1990--12/1995        15                                          NA                                          108                   151.5   84      120     235.5   *59*    355.5   *59*    
  Arun, 2011              United States            CGC based with int. ref.                                          From CGC, all received NST                           Yes                          NA                                                                                                                    Not reported           57                                          23                                          237                   108     84      46      192     *48*    238     *40*    
  Bayraktar, 2011         United States            CGC based with int. ref.                                          From CGC, with triple negative tumours               Yes                          NA                                                                                                                    1997--2010             94                                          20                                          101                   108     84      200     192     *48*    392     *65*    
  Bonadona, 2007          France                   Unselected cohort                                                 age diagnosis \< 46                                  Yes                          NA                                                                                                                    1/1995--1/1998         15                                          6                                           211                   151.5   84      176     235.5   *59*    411.5   *69*    
  Brekelmans, 2007        The Netherlands          CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Partly            x                                               x                                      \> 1//1/1980                                170                                         90                    759     87      47      176     134     *34*    310     *52*
  Brekelmans, 2007        The Netherlands          CGC based with int. ref.                                          From CGC                                             Yes                          NA                                                                                                                    \> 1/1/1980            170                                         90                                          238                   108     47      176     155     *39*    331     *55*    
  Budroni, 2009           Italy                    Unselected cohort                                                 \-                                                   Yes                          NA                                                                                                                    1997--2002             4                                           44                                          468                   151.5   63      74      214.5   *54*    288.5   *48*    
  Carroll, 2011           Ireland                  CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                                               x                      1997--2007                                  16                                          20                    108     64.5    26      59      90.5    *23*    149.5   *25*
  Chappuis, 2000          Canada                   Unselected cohort                                                 A. Jewish                                            Yes                          NA                                                                                                                    1/1986--11/1995        24[^b^](#t001fn003){ref-type="table-fn"}    8[^b^](#t001fn003){ref-type="table-fn"}     170                   300     100     176     400     *100*   576     *96*    
  Chappuis, 2005          Canada                   Unselected cohort                                                 A. Jewish                                            Yes                          NA                                                                                                                    1/1/1980--1/11/1995    30[^b^](#t001fn003){ref-type="table-fn"}    NA                                          248                   300     100     176     400     *100*   576     *96*    
  Chiappetta, 2010        Italy                    CGC based with int. ref.                                          From CGC                                             Yes                          NA                                                                                                                    1990--2002             31                                          23                                          62                    108     63      23      171     *43*    194     *32*    
  Cortesi, 2010           Italy                    CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  No                                                                                                       1988--2006                                  80                                          NA                    4912    87      47      176     134     *34*    310     *52*
  Cortesi, 2010           Italy                    Unselected cohort                                                 FH+                                                  Yes                          NA                                                                                                                    1988--2006             80                                          NA                                          931                   151.5   63      176     214.5   *54*    390.5   *65*    
  Cortesi, 2010           Italy                    CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  Yes               x                                                               x                      1988--2006                                  80                                          NA                    320     64.5    47      176     111.5   *28*    287.5   *48*
  Eccles, 2001            United Kingdom           CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  No                                                                                                       Unclear                                     75                                          NA                    162     64.5    21      115     85.5    *21*    200.5   *33*
  Eccles, 2001            United Kingdom           CGC based with int. ref.                                          from CGC                                             No                           NA                                                                                                                    Unclear                75                                          NA                                          67                    108     21      115     129     *32*    244     *41*    
  Eerola, 2001            Finland                  CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  No                                                                                                       1953--1995                                  32                                          43                    59517   87      26      59      113     *28*    172     *29*
  Eerola, 2001            Finland                  Unselected cohort                                                 FH+                                                  Yes                          NA                                                                                                                    1953--1995             32                                          43                                          284                   151.5   63      59      214.5   *54*    273.5   *46*    
  Einbeigi, 2001          Sweden                   CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  Yes               x                                               x                                      Not reported                                30                                          NA                    120     85.5    26      0       111.5   *28*    111.5   *19*
  Ellberg, 2010           Sweden                   Unselected cohort                                                 Only the CGC eligible Pts (4%) were tested           Partly                       NA                                                                                                                    Not reported           9                                           5                                           1663                  235.5   63      59      298.5   *75*    357.5   *60*    
  El-Tamer, 2004          United States            Unselected cohort                                                 A. jewish, age diagnosis \< 65                       Yes                          NA                                                                                                                    1/1989--1/1999         30[^b^](#t001fn003){ref-type="table-fn"}    21[^b^](#t001fn003){ref-type="table-fn"}    436                   216     100     115     316     *79*    431     *72*    
  Foulkes, 1997           Canada                   Unselected cohort                                                 A. jewish, age diagnosis \< 65                       Yes                          NA                                                                                                                    1/1990--11/1995        12[^b^](#t001fn003){ref-type="table-fn"}    NA                                          100                   151.5   100     120     251.5   *63*    371.5   *62*    
  Gaffney, 1998           United States            CGC based with ext. ref.                                          BRCA+, FH+                                           From cancer registry         No                                  No                                                                                                       1957--1994                                  30                                          20                    18278   256.5   68      59      324.5   *81*    383.5   *64*
  Gaffney, 1998           United States            CGC based with ext. ref.                                          BRCA+, FH+                                           From cancer registry         No                                  Yes               x                                               x               x                      1957--1994                                  30                                          20                    8409    256.5   68      23      324.5   *81*    347.5   *58*
  Goffin, 2003            Canada                   Unselected cohort                                                 A. Jewish \< 65                                      Yes                          NA                                                                                                                    01/1980--11/1995       30[^b^](#t001fn003){ref-type="table-fn"}    NA                                          248                   216     100     176     316     *79*    492     *82*    
  Goffin, 2003            Canada                   Unselected cohort                                                 A. Jewish \< 65                                      Yes                          NA                                                                                                                    1980--1995             28[^b^](#t001fn003){ref-type="table-fn"}    8[^b^](#t001fn003){ref-type="table-fn"}     215                   300     100     120     400     *100*   520     *87*    
  Gonzalez-Angulo, 2011   United States            Unselected cohort                                                 With triple negative tumours                         Yes                          NA                                                                                                                    1997--2006             12                                          3                                           62                    216     63      176     279     *70*    455     *76*    
  Goode, 2002             United Kingdom           Unselected cohort                                                 From cancer registry                                 Partly (56%)                 NA                                                                                                                    \> 01--1991            10                                          19                                          2400                  235.5   79      120     314.5   *79*    434.5   *72*    
  Goodwin, 2012           United States + Canada   CGC based with int. ref.                                          Mostly from CGC                                      Partly                       NA                                                                                                                    1991--1998             94                                          72                                          1550                  214.5   68      176     282.5   *71*    458.5   *76*    
  Hagen, 2009             Norway                   CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  Yes               x                                               x               x                      1980--2001                                  167                                         NA                    304     108     26      59      134     *34*    193     *32*
  Hamann, 2000            Germany                  CGC based with ext. ref.                                          BRCA+, from CGC                                      FH+ (BRCA- families)         Yes                                 No                                                                                                       1961--1994                                  36                                          NA                    49      150     84      120     234     *59*    354     *59*
  Heikkinen, 2009         Finland                  CGC based with ext. ref.                                          BRCA+, from CGC                                      Partly FH+                   Partly (25%)                        No                                                                                                       1997--2004                                  67                                          68                    2135    64·5    68      120     132·5   *33*    252·5   *42*
  Huzarski, 2013          Poland                   Unselected cohort                                                 age diagnosis \< 50, stage I-III                     Yes                          NA                                                                                                                    1996--2006             233[^b^](#t001fn003){ref-type="table-fn"}   NA                                          3112                  235.5   176     314.5   314.5   *79*    490.5   *82*    
  Jóhannsson, 1998        Sweden                   CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  No                                                                                                       1958--1995                                  40                                          NA                    28281   151.5   26      46      177.5   *44*    223.5   *37*
  Jóhannsson, 1998        Sweden                   CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  Yes               x                                                               x                      1958--1995                                  40                                          NA                    112     172.5   26      176     198.5   *50*    374.5   *62*
  Kirova, 2010            France                   CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                               x                                      1981--2000                                  19                                          8                     54      87      47      46      134     *34*    180     *30*
  Kirova, 2010            France                   CGC based with int. ref.                                          From CGC                                             Yes                          NA                                                                                                                    1981--2000             19                                          8                                           107                   108     63      120     171     *43*    291     *49*    
  Kirova, 2010            France                   CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Partly            x                                               x                                      1981--2000                                  19                                          8                     271     87      47      120     134     *34*    254     *42*
  Lee, 1999               United States            Unselected cohort                                                 affected relatives of B+/B- (kin-cohort-analyse)     Yes                          NA                                                                                                                    Not reported           35                                          23                                          979                   151.5   63      46      214.5   *54*    260.5   *43*    
  Lee, 2011               United States            CGC based with int. ref.                                          From CGC, with triple negative tumours               Yes                          NA                                                                                                                    1/1/1996--31/12/2004   46                                          NA                                          71                    43.5    63      176     106.5   *27*    282.5   *47*    
  Loman, 2000             Sweden                   CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  Yes               x                                               x                                      1995--1999                                  NA                                          54                    214     85.5    47      82      132.5   *33*    214.5   *36*
  Moller, 2002            Northern europe          CGC based with int. ref.                                          From CGC, with N0 tumours                            Yes                          NA                                                                                                                    Not reported           24                                          NA                                          108                   172.5   84      84      256.5   *64*    340.5   *57*    
  Moller, 2007            Norway + UK              CGC based with int. ref.                                          From CGC (20% DCIS tumours)                          Yes                          NA                                                                                                                    \< 12/2005             71                                          22                                          282                   214.5   63      120     277.5   *69*    397.5   *66*    
  Musolino, 2007          Italy                    CGC based with int. ref.                                          age diagnoses \< 40, from CGC                        Yes                          NA                                                                                                                    6/1999--12/2005        10                                          5                                           41                    108     37      139     145     *36*    284     *47*    
  Musolino, 2007          Italy                    CGC based with ext. ref.                                          BRCA+, age diagnosis \<40, from CGC                  age diagnosis \>45 and FH-   No                                  No                                                                                                       6/1999--12/2005                             10                                          5                     28      87      21      139     108     *27*    247     *41*
  Nisman, 2010            Israel                   CGC based with int. ref.                                          A. Jewish, from CGC                                  Yes                          NA                                                                                                                    5/2004--12/20078       7[^b^](#t001fn003){ref-type="table-fn"}     9[^b^](#t001fn003){ref-type="table-fn"}     66                    108     63      120     171     *43*    291     *49*    
  Pierce, 2000            USA, Canada              CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                               x                                      3/1980--12/1997                             54                                          17                    213     85.5    47      176     132.5   *33*    308.5   *51*
  Pierce, 2006            USA + Israel             CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                               x                                      by 04/2001                                  123                                         37                    445     108     47      176     155     *39*    331     *55*
  Plakhins, 2011          Latvia                   CGC based with int. ref.                                          from CGC (selection irrespective of FH)              Yes                          Yes                                 x                 x                                               x               Not reported           93[^b^](#t001fn003){ref-type="table-fn"}    NA                                          103                   108     63      144     171     *43*    315     *53*    
  Plakhins, 2013          Latvia                   CGC based with ext. ref. [^a^](#t001fn002){ref-type="table-fn"}   BRCA+, from CGC                                      BRCA-, from CGC              Yes                                 Yes                                                                               x                      2002--2008                                  71b                                         NA                    93      172.5   84      97      256.5   *64*    353.5   *59*
  Rennert, 2007           Israel                   Unselected cohort                                                 A. Jewish                                            Yes                          NA                                                                                                                    1/1987--1/1989         76[^b^](#t001fn003){ref-type="table-fn"}    52[^b^](#t001fn003){ref-type="table-fn"}    1189                  300     100     138     400     *100*   538     *90*    
  Rijnsburger, 2010       The Netherlands          CGC based with int. ref.                                          from CGC (part of a screening study)                 Yes                          NA                                                                                                                    11/1999--3/2006        42                                          34                                          256.5                 84      46      340.5   *85*    386.5   *64*            
  Robson, 1998            United States            Unselected cohort                                                 A. Jewish, age diagnosis \< 42                       Yes                          NA                                                                                                                    1/1992--12/1995        28[^b^](#t001fn003){ref-type="table-fn"}    58                                          151.5                 84      200     235.5   *59*    435.5   *73*            
  Robson, 1999            United States            Unselected cohort                                                 A. Jewish                                            Yes                          NA                                                                                                                    1/1980--12/1990        21[^b^](#t001fn003){ref-type="table-fn"}    7[^b^](#t001fn003){ref-type="table-fn"}     277                   216     100     138     316     *79*    454     *76*    
  Robson, 2004            United States            Unselected cohort                                                 A. jewish                                            Yes                          NA                                                                                                                    1/1980--11/1995        43[^b^](#t001fn003){ref-type="table-fn"}    14[^b^](#t001fn003){ref-type="table-fn"}    440                   216     100     176     316     *79*    492     *82*    
  Seynaeve, 2004          The Netherlands          CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Partly            x                                               x                                      1980--1995                                  21                                          2                     174     108     68      176     176     *44*    352     *59*
  Soumittra, 2009         India                    CGC based with int. ref.                                          From CGC                                             Yes                          NA                                                                                                                    Not reported           12                                          48                                          108                   37      23      145     *36*    168     *28*            
  Stoppa-Lyonnet, 2000    France                   CGC based with int. ref.                                          From CGC                                             Yes                          NA                                                                                                                    1/1991--7/1998         19                                          NA                                          91                    108     84      120     192     *48*    312     *52*    
  Tryggvadottir, 2013     Iceland                  Unselected cohort                                                 \-                                                   Yes                          NA                                                                                                                    1955--2004             NA                                          215[^b^](#t001fn003){ref-type="table-fn"}   2752                  235.5   100     120     335.5   *84*    455.5   *76*    
  Verhoog, 1998           The Netherlands          CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                               x                                      1969--1995                                  49                                          NA                    120     87      47      120     134     *34*    254     *42*
  Verhoog, 1999           The Netherlands          CGC based with ext. ref.                                          BRCA+, from CGC                                      From cancer registry         No                                  Yes               x                                               x                                      1960--1996                                  NA                                          28                    112     87      68      120     155     *39*    275     *46*
  Veronesi, 2005          Italy                    CGC based with int. ref.                                          From CGC                                             Yes                          NA                                                                                                                    \>1997                 9                                           30                                          86                    108     37      61      145     *36*    206     *34*    
  Vinodkumar, 2007        India                    Unselected cohort                                                 FH+                                                  Yes                          NA                                                                                                                    Not reported           11                                          NA                                          18                    151.5   42      59      193.5   *48*    252.5   *42*    
  Wagner, 1998            Austria                  CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                               x               x                      \>1970 (carriers) \>1981(non-c)             34                                          NA                    34      87      47      97      134     *34*    231     *39*
  Wagner, 1998            Austria                  CGC based with ext. ref.                                          BRCA+, from CGC                                      FH-                          No                                  Yes               x                                                                                      \>1970 (carriers) \>1981(non-c)             23                                          NA                    68      87      47      97      134     *34*    231     *39*
  Xu, 2012                China                    Unselected cohort                                                 Ancestry unclear (only A. Jewish mutations tested)   Yes                          NA                                                                                                                    1/1999--12/2005        52[^b^](#t001fn003){ref-type="table-fn"}    28[^b^](#t001fn003){ref-type="table-fn"}    280                   87      84      61      171     *43*    232     *39*    

*CGC = Clinical Genetic Centre; CGC based with ext*. *ref*. = *CGC based study with external reference group; CGC based with int*. *ref*. = *CGC based study with internal reference group; Unselected cohort = Unselected cohort study; FH = family history; NST = Neo-adjuvant systemic therapy; NA = not applicable;*

^*a*^ *Both carriers and non-carriers were identified in the CGC but because only a selection of the CGC population was included and matching was performed the study was defined as an" CGC based with ext*. *ref" type of study;*

^*b*^ *Only a selection of founder mutations was included*.

10.1371/journal.pone.0120189.t002

###### Results of studies included in the review (N = 66).
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  Author + year                             Mutation                                  Outcome                                   Unadjusted Risk estimates   Adjusted Risk estimates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ----------------------------------------- ----------------------------------------- ----------------------------------------- --------------------------- ------------------------- --- ------ -------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------ ------------------ ------- -------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Ansquer, 1998                             x                                                                                   X                                                                84                                                                               70                                           -14[\*](#t002fn002){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  x                                                                                                                                                         x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Worse                                                                                                                                                                                                                     
  Arun, 2011                                x                                                                                   X                                                                90.5                                                                             86.8                                         -3.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  x                                                                                                                                                         x                             73.5   72.1                                                                             -1.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                            x                                         X                                                                                                   90.5   100                                                                              9.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            x                                                                                                               x                             73.5   92.9                                                                             19.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  x                                         x                                         X                                                                                                   82     85                                                                               3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  x                                         x                                                                                                               x                             65     71                                                                               6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Bayraktar, 2011                           x                                         x                                         X                                                                85                                                                               93                                           8                                                             74      74                                                                                                 0                                          x                                                                                               0.52 (0.23--1.19)                                                                                                   0.51 (0.23--1.17)                                                                                     Age at diagnosis (\>40 vs \< = 40) and Clinical stage (1--3)
  x                                         x                                                                                                               x                             74     81                                                                               7                                                                                       55                 57      2                                                                                                  x                                          0.70 (0.40--1.23)                                                                                                                                          0.67 (0.38--1.19)                                                                                                                                              
  Bonadona, 2007                            x                                                                                   X                                                                89.6                                                                             93.3                                         3.7                                                                                                                                                                                                                                                                                                                 0.67 (0.16--2.77)                                                                                                   0.29 (0.04--2.26)                                                                                     Unclear, but probably: age at diagnosis, axilarry node status, grade, ER-status, PR-status, tumour size
  x                                                                                                                             X                                                         89.6   93.3                                                                             3.7                                                                                                                                                                                                                                                              0.67 (0.16--2.77)                                                                                                                                          0.29 (0.04--2.26)                                                                                                                                              
  x                                                                                                                                                         x                             90     100                                                                              10                                           x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  x                                                                                                                                                                                   x   78.2   93.3                                                                             15.1                                                                                                                                                                                                                                                             0.47 (0.12--1.94)                                                                                                                                          0.24 (0.03--1.82)                                                                                                                                              
  x                                         x                                         X                                                                                                   89.6   95                                                                               5.4                                                                                                                                                                                                                                                              0.50 (0.12--2.07)                                                                                                                                                                                                                                                                                                         
  x                                         x                                                                                   x                                                         89.6   95                                                                               5.4                                                                                                                                                                                                                                                              0.50 (0.12--2.07)                                                                                                                                                                                                                                                                                                         
  x                                         x                                                                                                               x                             100    88.8                                                                             -11.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  x                                         x                                                                                                                                         x   78.2   94.7                                                                             16.5                                                                                                                                                                                                                                                             0.37 (0.09--1.51)                                                                                                                                                                                                                                                                                                         
  Brekelmans, 2007                          x                                                                                   X                                                                75                                                                               69                                           -6                                                            55      50                                                                                                 -5                                                                                                                                         1.01 (0.75--1.37)[^c^](#t002fn005){ref-type="table-fn"}                                                             1.3 (0.91--1.85)                                                                                      Age at diagnosis, stage, adjuvant treatment, ER-status, morphology, histological grade, B(s)O, occurrence of contralateral breast cancer
  x                                                                                                                             x                                                         78     73                                                                               -5                                                                                      59                 62      3                                                                                                                                             0.89 (0.63--1.25) [^c^](#t002fn005){ref-type="table-fn"}                                                                                                   1.21 (0.83--1.76)                                                                                                                                              
  x                                                                                                                                                         x                             88     88                                                                               0                                                                                       79                 84      5                                                                                                                                             0.92 (0.56--1.51) [^c^](#t002fn005){ref-type="table-fn"}                                                                                                   0.84 (0.41--1.75)                                                                                                                                              
  x                                                                                                                                                                                   x   64     68                                                                               4                                                                                       50                 60      10                                                                                                                                            0.71 (0.52--0.96)[\*](#t002fn002){ref-type="table-fn"} [^c^](#t002fn005){ref-type="table-fn"}                                                              1.25 (0.78--1.92)                                                                                                                                              
                                            x                                         X                                                                                                   75     75                                                                               0                                                                                       55                 61      6                                                                                                                                                                                                                                                                                                        1.07 (0.66--1.74)                                                                                                                                              
                                            x                                                                                   x                                                         78     80                                                                               2                                                                                       59                 68      9                                                                                                                                                                                                                                                                                                        0.84 (0.48--1.47)                                                                                                                                              
                                            x                                                                                                               x                             88     83                                                                               -5                                                                                      79                 83      4                                                                                                                                                                                                                                                                                                        0.85 (0.26--2.77)                                                                                                                                              
                                            x                                                                                                                                         x   64     73                                                                               9                                                                                       50                 61      11                                                                                                                                                                                                                                                                                                       0.75 (0.44--1.29)                                                                                                                                              
  Brekelmans, 2007                          x                                                                                   X                                                                83                                                                               69                                           -14                                                           66      50                                                                                                 -16                                                                                                                                                                                                                                                                                                                                                                  
  x                                                                                                                             X                                                         87     73                                                                               -14                                                                                     70                 62      -8                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  x                                                                                                                                                         x                             88     88                                                                               0                                                                                       85                 84      -1                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  x                                                                                                                                                                                   x   73     68                                                                               -5                                                                                      61                 60      -1                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                            x                                         X                                                                                                   83     75                                                                               -8                                                                                      66                 61      -5                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                            x                                                                                   x                                                         87     80                                                                               -7                                                                                      70                 68      -2                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                            x                                                                                                               x                             88     83                                                                               -5                                                                                      85                 83      -2                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                            x                                                                                                                                         x   73     73                                                                               0                                                                                       61                 61      0                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Budroni, 2009                                                                       x                                         x                                                                91                                                                               81                                           -10                                                                                                                                                                                                                                                                                                                 0.70 (0.46--1.37) [^d^](#t002fn006){ref-type="table-fn"}                                                            0·80 (0·48--1·62)                                                                                     Tumour stage
  Carroll, 2011                             x                                         x                                         x                                                                92                                                                               97.5                                         5.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Chappuis, 2000                            x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Worse[\*](#t002fn002){ref-type="table-fn"}                                                                        Worse                                        Age at diagnosis, tumour size, nuclear grade, LN-status, ER-status, p27kip expression
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                   x   82     58                                                                               -24[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                         2.7 (1.4--5.2) [\*](#t002fn002){ref-type="table-fn"}                                                                                                       2.1 (1.0--4.3)[\*](#t002fn002){ref-type="table-fn"}                                                                                                            
  Chappuis, 2005                            x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                                    82†                                                                              74†                                          -8                                         x                  71†     61†                                                                                                -10                                        x                                                                                               1.9 (0.99--3.6)                                                                                                     0.8 (0.4--1.6)                                                                                        Age at diagnosis, tumour size, nuclear grade, LN-status, ER-status, Cyclin E expression, p27kip expression
  Chiappetta, 2010                          x                                                                                   x                                                                94                                                                               72                                           -22[\*](#t002fn002){ref-type="table-fn"}                      83      68                                                                                                 -15[\*](#t002fn002){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                                                                         
                                            x                                         x                                                                                                   94     92                                                                               -2                                                                                      83                 79      -4                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Cortesi, 2010                             x                                                                                   x                                                                82                                                                               94                                           12[\*](#t002fn002){ref-type="table-fn"}    x                  73      77                                                                                                 4[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                         0.29 (0.13--0.62)[\*](#t002fn002){ref-type="table-fn"}                                                Stage, ER-status, PR-status, grade, age at diagnosis, chemotherapy
  x                                                                                                                                                         x                             86     86                                                                               0                                            x                                          75                 70      -5                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Cortesi, 2010                             x                                                                                   x                                                                88                                                                               94                                           6                                          x                  77      77                                                                                                 0                                                                                                                                                                                                                                                                                                                                                                    
  x                                                                                                                                                         x                             83     86                                                                               3                                            x                                          70                 70      0                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Cortesi, 2010                             x                                                                                   x                                                                90                                                                               96                                           6[\*](#t002fn002){ref-type="table-fn"}     x                  73      85                                                                                                 12[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                              
  Eccles, 2001                              x                                                                                   x                                                                82                                                                               81                                           -1                                         x                  73      75                                                                                                 2                                          x                                                                                                                                                                                                                                                                                                                         
  x                                                                                                                                                         x                             67     64                                                                               -3                                           x                                          56                 55      -1                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Eccles, 2001                              x                                                                                   x                                                                92                                                                               81                                           -11                                        x                  81      75                                                                                                 -6                                         x                                                                                                                                                                                                                                                                                                                         
  x                                                                                                                                                         x                             64     64                                                                               0                                            x                                          44                 55      10                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Eerola, 2001                              x                                                                                   x                                                                78                                                                               67                                           -11                                                                                                                                                                                                                                                                                                                                                                                                                                     1.3 (0.63--2.7)                                                                                       Stage, age at diagnosis, calendar year of diagnosis, follow-up year, family history
                                            x                                         x                                                                                                   78     77                                                                               -1                                                                                                                                                                                                                                                                                                                                                                                                                          0.78 (0.39--1.57)                                                                                                                                              
  Eerola, 2001                              x                                                                                   x                                                                86                                                                               67                                           -19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                            x                                         x                                                                                                   86     77                                                                               -9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Einbeigi, 2001                            x                                                                                   x                                                                80                                                                               85                                           5                                          x                  65      70                                                                                                 5                                          x                                                                                                                                                                                                                                                                                                                         
  Ellberg, 2010                             x                                         x                                         x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.90 (0.99--3.65)^d^                                                                                                                                                         Worse[\*](#t002fn002){ref-type="table-fn"}   Age at diagnosis, tumour size, number LN+, occurrence of distant metastasis
  El-Tamer, 2004                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                91.3                                                                             90.7                                         -0.6                                                          81      79.4                                                                                               -1.6                                                                                                                                                                                                                                                                                                                                                                 
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                       x                                                         91.6   90.7                                                                             -0.9                                                                                    84.6               79.4    -5.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                                   x                             92     72                                                                               -20[\*](#t002fn002){ref-type="table-fn"}     x                                          91                 72      -19[\*](#t002fn002){ref-type="table-fn"}                                                           x                                                                                                                                                                                                                                                                                                                                                                    
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                                                             x                                                                                                                                                                                                                                                                                                                                                                                                                                                            Equal                                                                                                                                                                                                                     
                                            x[^b^](#t002fn004){ref-type="table-fn"}   x                                                                                                   91.3   94.7                                                                             3.4                                                                                     81                 94.7    13.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                         91.6   94.7                                                                             3.1                                                                                     84.6               94.7    10.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                            x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                             92     83                                                                               -9                                           x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                            x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                   x                                                                                                                                                                                                                                                                                                                                                                                                                                                            Equal                                                                                                                                                                                                                     
  Foulkes, 1997                             x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                   x          95                                                                               80                                           -15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Gaffney, 1998                             x                                                                                   x                                                                69                                                                               75                                           6                                                             50      65                                                                                                 15                                         x                                                                                                                                                                                                                                                                                                                         
                                            x                                         x                                                                                                   69     73                                                                               4                                                                                       50                 50      0                                                                                                  x                                                                                                                                                                                                                                                                                                                                                                    
  x                                         x                                         x                                                                                                   69     75                                                                               5                                            x                                          50                 55      5                                                                                                  x                                                                                                                                                                                                                                                                                                                                                                    
  Gaffney, 1998                             x                                                                                   x                                                                75                                                                               75                                           0                                          x                  55      65                                                                                                 10                                         x                                                                                                                                                                                                                                                                                                                         
                                            x                                         x                                                                                                   70     73                                                                               3                                            x                                          60                 50      -10                                                                                                x                                                                                                                                                                                                                                                                                                                                                                    
  x                                         x                                         x                                                                                                   70     75                                                                               5                                            x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Goffin, 2003                              x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                85                                                                               72                                           -13                                        x                  75      57                                                                                                 -18                                        x                                                                                               1.9 (0.99--3.6)                                                                                                     1.4 (0.7--2.9)                                                                                        Tumour size, grade, LN-status, P53-expression
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                                                             x   82†    62†                                                                              -20[\*](#t002fn002){ref-type="table-fn"}     x                                                                                                                                                                                                                   1.6 (0.9--2.9)                                                                                                                                             1.2 (0.7--2.4)                                                                                                                                                 
  Goffin, 2003                              x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                               x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1.8 (0.96--3.2)                                                                                                     1.1 (0.6--2)                                                                                          Tumour size, nuclear grade, ER-status, LN-status, P53 expression, glomeruloid microvascular proliferation
  Gonzalez-Angulo, 2011                     x                                         x                                         x                                                                52.8                                                                             73.3                                         20.5                                                                                                                                                                                                                                                                                                                                                                                                                                    0.45 (0.16--1.29)                                                                                     Stage, nuclear grade
  x                                         x                                                                                                               x                             51.7   86.2                                                                             34.5[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                   0.17 (0.04--0.71)[\*](#t002fn002){ref-type="table-fn"}                                                                                                         
  Goode, 2002                               x                                                                                   x                                                                85                                                                               42                                           -43[\*](#t002fn002){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                        4.14 (1.32--13)[\*](#t002fn002){ref-type="table-fn"}                                                                1.99 (0.47--8.45)                                                                                     Grade, tumour type
                                            x                                         x                                                                                                   85     70                                                                               -15                                          x                                          77                 70      -1                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Goodwin, 2012                             x                                                                                   x                                                                89                                                                               86                                           -3                                         x                  75      68                                                                                                 -7                                         x                                                                                               1·43 (0·92--2·23)                                                                                                   0·99 (0·62--1·59)                                                                                     Age at diagnosis, T-stage, nodal stage, grade, ER/PgR status, year of diagnosis
  x                                                                                                                                                                                   x   86     82                                                                               -4                                           x                                          76                 76      0                                                                                                  x                                          1.19 (0.74--1.89)                                                                                                                                          0.83 (0.51--1.35)                                                                                                                                              
                                            x                                         x                                                                                                   90     88                                                                               -2[\*](#t002fn002){ref-type="table-fn"}      x                                          76                 69      -7[\*](#t002fn002){ref-type="table-fn"}                                                            x                                          1.82 (1.15--2.86)[\*](#t002fn002){ref-type="table-fn"}                                                                                                     1.12 (0.70--1.79)                                                                                                                                              
                                            x                                                                                                                                         x   86     75                                                                               -11[\*](#t002fn002){ref-type="table-fn"}     x                                          79                 73      -6[\*](#t002fn002){ref-type="table-fn"}                                                            x                                          1.63 (1.02--2.6)[\*](#t002fn002){ref-type="table-fn"}                                                                                                      1.00 (0.62--1.61)                                                                                                                                              
  Hagen, 2009                               x                                                                                   x                                                                85                                                                               90                                           5                                          x                  74      76                                                                                                 2                                          x                                                                                                                                                                                                                                                                                                                         
  Hamann, 2000                              x                                                                                   x                                                                87.1                                                                             83.9                                         -3.2                                                          81.3    71.7                                                                                               -9.6                                                                                                                                                                                                                                                                                                                                                                 
  x                                                                                                                                                         x                             86.9   53.3                                                                             -33.6[\*](#t002fn002){ref-type="table-fn"}                                              76                 53.3    -22.7[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                              
  Heikkinen, 2009                           x                                                                                                               x                                    93                                                                               83                                           -10[\*](#t002fn002){ref-type="table-fn"}   x                  84      76                                                                                                 -8[\*](#t002fn002){ref-type="table-fn"}    x                                                                                               1.67 (0.99--2.82)                                                                                                                                                            Equal                                        Grade, PR-status, HER2, T-status, N-status, M-status
                                            x                                                                                   x                                                         93     87                                                                               -6[\*](#t002fn002){ref-type="table-fn"}      x                                          84                 63.7    -20.3[\*](#t002fn002){ref-type="table-fn"}                                                         x                                          2.34 (1.5--3.66)[\*](#t002fn002){ref-type="table-fn"}                                                                                                      2.06 (1.03--4.15)[\*](#t002fn002){ref-type="table-fn"}                                                                                                         
  Huzarski, 2013                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                89                                                                               88                                           -1                                         x                  82.2    80.9                                                                                               -1.3                                                                                                                                       1.13 (0.83--1.57                                                                                                    1.81 (1.26--2.61)[\*](#t002fn002){ref-type="table-fn"}                                                year of birth, age at diagnosis, ER status, PR status, HER2 status, Size, Nodal status, Oophorectomy (time-varying), tamoxifen, chemotherapy
  Jóhannsson, 1998                          x                                                                                   x                                                                68                                                                               68                                           0                                          x                  45      57                                                                                                 12                                         x                                                                                               1.5 (0.9--2.4) [^d^](#t002fn006){ref-type="table-fn"}                                                                                                                                                                     
  Jóhannsson, 1998                          x                                                                                   x                                                                80                                                                               62                                           -18                                        x                  62      56                                                                                                 -6                                         x                                                                                               1.5 (0.6--3.7)                                                                                                                                                                                                            
  Kirova, 2010                              x                                         x                                                                                               x          90                                                                               86                                           -4                                         x                  70      65                                                                                                 -5                                         x                                                                                                                                                                                                                                                                                                                         
  Kirova, 2010                              x                                         x                                         x                                                                98                                                                               92                                           -6                                         x                  82      76                                                                                                 -6                                         x                                                                                                                                                                                                                                                                                                                         
  x                                         x                                                                                                               x                             82     86                                                                               4                                            x                                          77                 65      -12                                                                                                x                                                                                                                                                                                                                                                                                                                                                                    
  Kirova, 2010                              x                                         x                                         x                                                                92                                                                               92                                           0                                          x                  90      76                                                                                                 -14                                        x                                                                                                                                                                                                                                                                                                                         
  x                                         x                                                                                                               x                             89     86                                                                               -3[\*](#t002fn002){ref-type="table-fn"}      x                                          79                 65      -14[\*](#t002fn002){ref-type="table-fn"}                                                           x                                          1.8 (1--3.3)[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                         
  Lee, 1999                                 x                                                                                   x                                                                78                                                                               79                                           1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                            x                                         x                                                                                                   78     65                                                                               -13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  x                                         x                                         x                                                                                                   78     74                                                                               -4                                                                                      61                 61      0                                                                                                  x                                          1.04 (0.7--1.55) [^d^](#t002fn006){ref-type="table-fn"}                                                                                                                                                                                                                                                                   
  Lee, 2011                                 x                                                                                   x                                                                73.9                                                                             82.1                                         8.2                                                                                                                                                                                                                                                                                                                 0.58 (0.25--1.25)                                                                                                   0.73                                                                                                  Age at diagnosis, stage
  x                                                                                                                             x                                                         73.9   82.1                                                                             8.2                                                                                                                                                                                                                                                              0.58 (0.25--1.25)                                                                                                                                          0.73                                                                                                                                                           
  x                                                                                                                                                         x                             80.2   89.6                                                                             9.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  x                                                                                                                                                                                   x   69.9   75.6                                                                             5.7                                                                                                                                                                                                                                                              0.79 (0.38--1.58)                                                                                                                                          0.9                                                                                                                                                            
  Loman, 2000                                                                         x                                         x                                                                84                                                                               72                                           -12                                        x                  70      58                                                                                                 -12                                        x                                                                                               1.6 (0.98--2.7)                                                                                                                                                                                                           Stage
                                            x                                                                                   x                                                         90     76                                                                               -14[\*](#t002fn002){ref-type="table-fn"}     x                                          79                 59      -20[\*](#t002fn002){ref-type="table-fn"}                                                           x                                          2 (1.2--3.4)[\*](#t002fn002){ref-type="table-fn"}                                                                                                          1.6 (0.85--3.1)                                                                                                                                                
  Moller, 2002                              x                                                                                                                                         x          96                                                                               75                                           -21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Equal                                        Grade, ER-status
  Moller, 2007                              x                                                                                   x                                                                92                                                                               73                                           -19[\*](#t002fn002){ref-type="table-fn"}                      86      52                                                                                                 -34[\*](#t002fn002){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                                                                         
                                            x                                         x                                                                                                   92     96                                                                               4                                                                                       86                 96      10                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Musolino, 2007                            x                                         x                                         x                                                                93                                                                               93                                           0                                          x                  77      82                                                                                                 5                                          x                                                                                                                                                                                                                                                                                                                         
  x                                         x                                                                                                               x                             86     78                                                                               -8                                           x                                          81                 78      -3                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Musolino, 2007                            x                                         x                                         x                                                                100                                                                              93                                           -7                                         x                  100     82                                                                                                 -18                                        x                                                                                                                                                                                                                                                                                                                         
  x                                         x                                                                                                               x                             94     78                                                                               -16                                          x                                          81                 78      -3                                                                                                 x                                                                                                                                                                                                                                                                                                                                                                    
  Nisman, 2010                              x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                                         x          77.8                                                                             89.7                                         11.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Equal                                        Stage, serum TK1 activity, presence of necrosis, vascular invasion, tumour grade, ER-status, PR-status
  Pierce, 2000                              x                                         x                                         x                                                                91                                                                               86                                           -5                                                                                                                                                                                                                                                                                                                  1.18                                                                                                                                                                                                                      
  x                                         x                                                                                   x                                                         91     92                                                                               1                                                                                                                                                                                                                                                                0.71                                                                                                                                                                                                                                                                                                                      
  x                                         x                                                                                                               x                             80     78                                                                               -2                                                                                                                                                                                                                                                               1.36                                                                                                                                                                                                                                                                                                                      
  Pierce, 2006                              x                                         x                                                                                               x          95                                                                               95                                           0                                          x                  91      88                                                                                                 -3                                                                                                                                         1.37                                                                                                                1.37 (0.77--2.42)                                                                                     Age at diagnosis, stage, margins, tamoxifen, chemotherapy
  Plakhins, 2011                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                Only survival % of separate mutations. Therefore, not taken into account here.                                                                                           1.1 (0.81--1.48)           Tumour size (\<5cm vs \>5cm), axillary node status (neg vs pos), age at diagnosis (\<50 vs \>50)                                                                                                                                                                                                                                                                                                                                                                        
  Plakhins, 2013                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                82.02                                                                            84.47                                        2.45                                                          72.36   73.9                                                                                               1.54                                                                                                                                                                                                                                                                                                                                                                 
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                       x                                                                                                                                                                                                                                         79.34              80.15   0.81                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Rennert, 2007                             x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                                                                                                                                                                                                            51      49                                                                                                 -2                                                                                                                                         1.09 (0.79--1.51)                                                                                                   1.13 (0.78--1.66)                                                                                     Age at diagnosis, tumour size, LN-status, M-status
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                       x                                                                                                                                                                                                                                         67                 67      0                                                                                                                                             1.08 (0.72--1.63)                                                                                                                                          0.76 (0.45--1.3)                                                                                                                                               
                                            x[^b^](#t002fn004){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                                   51                 48      -3                                                                                                                                            1.07 (0.73--1.58)                                                                                                                                          1.2 (0.77--1.86)                                                                                                                                               
                                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                                                                                                                                                                                         67                 56      -11                                                                                                                                           1.42 (0.92--2.19)                                                                                                                                          1.31 (0.8--2.15)                                                                                                                                               
  Rijnsburger, 2010                         x                                         x                                         x                                                                100                                                                              92.7                                         -7.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  x                                         x                                                                                                                                         x   100    83.9                                                                             -16.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Robson, 1998                              x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}   x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Equal                                                                                                                                                          Stage, axillary node status
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                             69     65                                                                               -4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Equal                                                                                                 
  Robson, 1999                              x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                                                                                                                                                                                                            80.6    63.3                                                                                               -17[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                             LN-status / tumour stage, age at diagnosis (only for BCSS)
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                       x                                                                                                                                                                                                                                         87.2               67.3    -19.9[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                              
  x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                                                             x                                                                                                                                                                                   83.9               58.3    -25.6[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                               1.7 (0.66--4.36)                                                                                                                                               
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}   x                                                                                                   83     82                                                                               -1[\*](#t002fn002){ref-type="table-fn"}                                                 80.6               66      -14.6[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                              
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                         95.9   85.3                                                                             -10.6[\*](#t002fn002){ref-type="table-fn"}                                              87.2               71.9    -15.3[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                               2.08 (0.79--5.44)                                                                                                                                              
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                             95.5   85.1                                                                             -10.4                                                                                   93.1               78      -15.1                                                                                                                                         1.79 (0.64--5.03)                                                                                                                                                                                                                                                                                                         
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                                                                                   x   90.5   74.1                                                                             -16.4[\*](#t002fn002){ref-type="table-fn"}                                              84.3               66.3    -18.1[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                               1.45 (0.6--3.49)                                                                                                                                               
  Robson, 2004                              x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                                    92                                                                               80                                           -12[\*](#t002fn002){ref-type="table-fn"}   x                  86      62                                                                                                 -24[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                       2.39 (1.2--4.75) [\*](#t002fn002){ref-type="table-fn"}                                                Age at diagnosis, tumour size, axillary node status
                                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                                                                                                                                                                                         86                 84.5    -1.5                                                                                                                                                                                                                                                                                                                                                              Equal                                                                                                 
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                                                                                                                                                                                                         86                 67      -19[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                
  x[^b^](#t002fn004){ref-type="table-fn"}   x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                             96     92                                                                               -4                                           x                                          92                 88      -4                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Seynaeve, 2004                            x                                                                                   x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1.76 (0.72--4.3)                                                                                      Age at diagnosis, tumour size
  Soumittra, 2009                           x                                         x                                         x                                                                78                                                                               75                                           -3                                         x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  x                                         x                                                                                                               x                             72     75                                                                               3                                            x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Stoppa-Lyonnet, 2000                      x                                                                                   x                                                                85                                                                               49                                           -36[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                            5.1[\*](#t002fn002){ref-type="table-fn"}                                                                            3.5 (1.3--9.7) [\*](#t002fn002){ref-type="table-fn"}                                                  Nodal status, ER-status (only for MFS)
  x                                                                                                                             x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Worse[\*](#t002fn002){ref-type="table-fn"}                                                                          Worse[\*](#t002fn002){ref-type="table-fn"}                                                            
  x                                                                                                                                                         x                             79     54                                                                               -25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  x                                                                                                                                                                                   x   84     18                                                                               -66[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                         3.5[\*](#t002fn002){ref-type="table-fn"}                                                                                                                   2.6 (1--6.5) [\*](#t002fn002){ref-type="table-fn"}                                                                                                             
  Tryggvadottir, 2013                                                                 x[^b^](#t002fn004){ref-type="table-fn"}                               x                                    85                                                                               80                                           -5[\*](#t002fn002){ref-type="table-fn"}    x                  72      53                                                                                                 -19[\*](#t002fn002){ref-type="table-fn"}                                                                                                   1.61 (1.32--1.96)[^d^](#t002fn006){ref-type="table-fn"}                                                             0.98 (0.64--1.48)                                                                                     year of birth, year of diagnosis, tumour size, nodal status, grade, ER status, diploidy
  Verhoog, 1998                             x                                                                                   x                                                                69                                                                               63                                           -6                                                            46      53                                                                                                 6                                          x                                                                                               1.04 (0.63--1.71)                                                                                                   1.21 (0.72--2.04)                                                                                     Tumour stage
  x                                                                                                                             x                                                         71     64                                                                               -7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  x                                                                                                                                                         x                             51     49                                                                               -2                                                                                                                                                                                                                                                               1 (0.65--1.55)                                                                                                                                             1.09 (0.7--1.7)                                                                                                                                                
  Verhoog, 1999                                                                       x                                         x                                                                75                                                                               74                                           -1                                                                                                                                                                                                                                                                                                                  0.75 (0.37--1.51)                                                                                                   0.59 (0.27--1.29)                                                                                     Stage
                                            x                                                                                   x                                                         76     77                                                                               1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                            x                                                                                                               x                             52     52                                                                               0                                                                                                                                                                                                                                                                0.92 (0.52--1.62)                                                                                                                                          0.84 (0.44--1.63)                                                                                                                                              
  Veronesi, 2005                            x                                         x                                         x                                                                90                                                                               100                                          10                                         x                  90      88                                                                                                 -2                                                                                                                                                                                                                                                             1.1 (0.3--4.9)                                                                                        Age at diagnosis, grade
  x                                         x                                                                                                               x                             81     74                                                                               -5                                           x                                          60                 51      -9                                                                                                                                                                                                                                                                                                       0.9 (0.2--5.3)                                                                                                                                                 
  Vinodkumar, 2007                          x                                                                                   x                                                                No survival % because KM-figure of bad quality.                                  3.7[\*](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Wagner, 1998                                                                        x                                         x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Equal                                                                                                                                                          
                                            x                                                                                                               x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Equal                                                                                                                                                                                                                     
  Wagner, 1998                              x                                                                                   x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Equal                                                                                                                                                          
  x                                                                                                                                                         x                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Equal                                                                                                                                                                                                                     
  Xu, 2011                                  x[^b^](#t002fn004){ref-type="table-fn"}                                                                         x                                    85                                                                               87                                           2                                                                                                                                                                                                                                                                                                                                                                              Equal                                                                                                                                                          
                                            x[^b^](#t002fn004){ref-type="table-fn"}                                             x                                                         85     91                                                                               6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

*OS = overall survival; BCSS = breast cancer-specific survival; RFS = recurrence-free survival; MFS = metastasis-free survival; F = 5/10-year survival (%) was estimated from the Kaplan-meier figure published in the paper;*

\**Significant result;*

^*a*^ *When no risk estimates were reported but analyses were clearly done and the difference in survival was mentioned in the article*, *then the difference is described here;*

^*b*^ *Only a selection of founder mutations was included;*

^*c*^ *Risk estimate from other publication on the same study population (Brekelmans (2007)*: *extra risk estimates from Brekelmans (2006); Chappuis (2005)*: *extra risk estimates from Foulkes (2004); Goffin (2003)*: *extra risk estimates from Chappuis (2000));*

^*d*^ *Adjusted for age and/or calendar year of diagnosis*.

We performed a systematic review of all studies published reporting overall survival and/or breast cancer-specific survival and/or metastasis-free survival and/or recurrence-free survival related to *BRCA* mutation carriership. We systematically reviewed important differences in design between the studies and assessed their methodological rigor using a specially developed scoring-system aiming to give the best evidence regarding the prognosis of *BRCA1*- and *BRCA2*-associated tumours. We explored whether these differences could explain the discrepancies in outcomes between the studies. Because clinico-pathological features of the tumour are important prognostic factors and *BRCA1*-associated breast cancers are known to differ in this respect from tumours not associated with *BRCA* mutations, we paid special attention to a possible role for these factors as confounders or mediators in the association between *BRCA1* and *BRCA2* mutation carriership and breast cancer survival.

Materials and Methods {#sec006}
=====================

Search strategy and selection of relevant literature {#sec007}
----------------------------------------------------

Studies were identified through a systematic search in Pubmed until August 2013 with no language restrictions using the following terms as free text terms and available MeSH terms, shown in *italics*; '(BRCA\* mutation) AND (*survival* or *prognosis* or outcome or mortality or relapse or recurrence) AND (*breast neoplasms* or breast neoplasm or breast cancer or breast tumour)'; no limits were set ([Fig. 1](#pone.0120189.g001){ref-type="fig"}). References cited in relevant review papers were hand-searched for additional papers.

![Flow diagram of the inclusion process of papers and studies in the review.\
OS = Overall survival; BCSS = Breast cancer-specific survival; MFS = Metastasis-free survival; RFS = Recurrence-free survival.](pone.0120189.g001){#pone.0120189.g001}

One reviewer (AJvdB) browsed the title and abstract of the papers for their eligibility for the topic of research; i.e. the association between *BRCA1* and/or *BRCA2* mutation carriership and breast cancer survival. After this first selection, two reviewers (AJvdB and MKS) independently selected papers based on the following criteria: studies should be original reports and *BRCA1/2* mutation status should be known; we accepted studies in which less than 50% of the carrier group was identified by linkage (identification of individuals with a high probability of having a *BRCA* mutation by determination of disease patterns in high-risk families, possibly combined by identifying genetic markers that are co-inherited with the disease \[[@pone.0120189.ref005]\]) instead of by testing. In addition, studies should have included at least ten carriers of a *BRCA1* and/or *BRCA2* mutation, and outcomes reported should include overall survival and/or breast cancer-specific survival and/or metastasis-free survival and/or recurrence-free survival. To allow comparison between as many studies as possible, we focussed on 5- and 10-year survival estimates. When multiple studies using the same study population had been published, the study with the largest number of subjects and longest follow-up time was included. If studies used the same study population but reported different mutations and/or outcomes, each mutation type and outcome combination was included separately ([Fig. 1](#pone.0120189.g001){ref-type="fig"}). Disagreement on the inclusion of one paper was solved by consensus.

Quality scoring system {#sec008}
----------------------

Because no specific quality assessment scoring system was available for this research topic, we developed a scoring system ([S1 Supporting Information](#pone.0120189.s001){ref-type="supplementary-material"}, part A) including general methodological aspects as well as specific aspects of studies examining the association between *BRCA1/2* mutation carriership and breast cancer survival, following the method of Monninkhof and colleagues \[[@pone.0120189.ref006]\]. The potential forms of bias were categorized into three main types: selection bias, misclassification bias and confounding/accounting for mediating variables, contributing at most 300 points, 100 points and 200 points, respectively, to the quality scoring, representing the relative weights of 3:1:2 (additional information: [S1 Supporting Information](#pone.0120189.s001){ref-type="supplementary-material"}, part B). For each paper a quality score from 0 (potential for having extensive bias) to maximum 600 (less bias potential) could be assigned. When considering unadjusted survival outcomes, the scores for confounding/accounting for mediating variables (= 200 points) were excluded and a maximum score of 400 could be attained. Survival outcomes without adjustment or with adjustment for age or year at diagnosis alone in the analysis were considered unadjusted outcomes; survival outcomes adjusted for tumour characteristics and/or treatment in the analysis were considered adjusted outcomes (one exception to this were outcomes from studies where matching on tumour characteristics was performed (n = 7 \[[@pone.0120189.ref007]--[@pone.0120189.ref013]\]); these outcomes were included as unadjusted since in five of these studies \[[@pone.0120189.ref008],[@pone.0120189.ref010]--[@pone.0120189.ref013]\] only absolute survival differences were reported).

Two reviewers (AJvdB and MKS) independently assessed study quality for each included paper. Scores were compared thereafter and disagreements were solved by consensus or consultation of a third reviewer (FEvL).

Study classification {#sec009}
--------------------

All studies were categorized according to quality into two groups; studies achieving at least 50% of the maximum score (high quality (HQ) studies) and studies achieving less than 50%. This arbitrary cut-off was chosen upfront with the rationale to prevent studies with a high potential for bias to contribute to the evidence. However, sensitivity analyses were performed including all studies.

Furthermore, studies were classified into three types based on the method of patient inclusion: studies that included *BRCA1/2* mutation carriers mostly from a clinical genetic centre (CGC), and compared them with an external comparison group of non-carriers, or so called 'non-carriers' who were in fact untested patients assumed to be largely non-carriers, from the population or hospital (further referred to as 'CGC based studies with external reference group'); studies that included both tested carriers and confirmed non-carriers from the CGC ('CGC based studies with internal reference group'); and studies that tested a group of breast cancer patients from the hospital or general population, unselected for family history, for *BRCA1/2* mutation carriership ('Unselected cohort studies').

Data representation and analyses {#sec010}
--------------------------------

All data were taken from the papers; no attempt was made to request individual data from the researchers. All analyses were performed separately for the different *BRCA* mutations, stratified for all different survival outcomes. Significance testing was not used in the analyses, except in the standard meta-analyses on studies which reported hazard ratios.

A best-evidence synthesis tool ([S2 Supporting Information](#pone.0120189.s002){ref-type="supplementary-material"}; developed by Monninkhof and colleagues \[[@pone.0120189.ref006]\], adapted by the authors for this review) was used to score the evidence, taking into account the study quality and consistency of the results. Here only the HQ studies, with at least 50% of the attainable quality score, were considered. According to our criteria, at least four HQ studies were needed to generate sufficient evidence. Specific classification of the evidence is shown in [S2 Supporting Information](#pone.0120189.s002){ref-type="supplementary-material"}. For the best-evidence synthesis, a better survival for *BRCA1/2* carriers compared to 'non-carriers' was arbitrarily defined as an absolute survival difference ≥10% or a risk estimate ≤0.88; a worse survival as an absolute survival difference ≥10% or a risk estimate ≥1.14; no association as an absolute survival difference \<10% and a risk estimate between 0.88 and 1.14. These cut-offs were chosen arbitrarily considering a difference of 10% to certainly be of clinical relevance, and with the rationale that the methods used were not sensitive enough to detect smaller differences. In the sensitivity analysis also other cut-offs were used.

The best-evidence synthesis was performed irrespective of statistical significance ([S2 Supporting Information](#pone.0120189.s002){ref-type="supplementary-material"}). Sensitivity analyses were performed using all studies (irrespective of study quality), using only 'unselected cohort studies', using only significant results (*P* \< 0.05), and using different cut-offs of the definition of better and worse survival for carriers compared to 'non-carriers' without consideration of statistical significance of individual studies ([S9 Supporting Information](#pone.0120189.s009){ref-type="supplementary-material"}).

To estimate the average effect-size in the best-evidence synthesis, meta-analyses were performed using the HQ studies; this was only done for the mutation and outcome combinations where sufficient evidence, i.e. \>4 HQ studies, was available. For the absolute survival differences, pooled estimates were calculated using weighting based on the number of included *BRCA1* or *BRCA2* mutation carriers per study (weight per study (%) = (n of carriers in that specific study / total n of carriers of all studies which are used to form the pooled estimate)\*100). In most papers 95% confidence intervals, standard errors or standard deviation of absolute survival differences were not reported hence these could not be taken into account. Statistical heterogeneity was based on subjective indications using the forest plots. For the hazard ratios (HR), pooled estimates were calculated and statistical heterogeneity was assessed using Random effect analyses, which is designed to estimate the mean effect size from a range of studies while accounting for heterogeneity across the studies \[[@pone.0120189.ref014]\].

To examine whether the heterogeneity between the results could be explained by different aspects of the study quality, risk estimates and quality scores per bias of all studies were graphically displayed. Funnel plots were used to investigate possible publication bias \[[@pone.0120189.ref015]\]. Statistical analyses were performed using STATA-11.2.

Results {#sec011}
=======

Until August 2013, 1067 papers were identified in the Pubmed database, of which 66 studies from 55 papers matched the inclusion criteria and contributed data ([Fig. 1](#pone.0120189.g001){ref-type="fig"}).

The main characteristics and results of the 66 included studies \[[@pone.0120189.ref007]--[@pone.0120189.ref013],[@pone.0120189.ref016]--[@pone.0120189.ref063]\] are shown in [Table 1](#pone.0120189.t001){ref-type="table"} and [Table 2](#pone.0120189.t002){ref-type="table"} respectively. All studies were published after 1997; the numbers of included carriers ranged from 10 to 233. Of these 66 studies, 12 studies \[[@pone.0120189.ref022],[@pone.0120189.ref023],[@pone.0120189.ref028],[@pone.0120189.ref030]--[@pone.0120189.ref032],[@pone.0120189.ref039],[@pone.0120189.ref045],[@pone.0120189.ref049],[@pone.0120189.ref051]--[@pone.0120189.ref053]\] were performed in an Ashkenazi Jewish study population and tested only the three founder mutations.

Most studies (n = 25) compared *BRCA1/2* mutation carriers with an external 'non-carrier' group: 'CGC based studies with external reference group'; 18 were 'CGC based studies with internal reference group' and 23 were 'Unselected cohort studies' ([Table 1](#pone.0120189.t001){ref-type="table"}).

When considering unadjusted outcomes and only taking into account selection and misclassification bias in the analysis, the quality scores of the included studies ranged from 85.5 (21% of maximum) to 400 (100% of maximum); 29 studies (44%) were considered HQ with scores \>200 ([Fig. 2A](#pone.0120189.g002){ref-type="fig"} and [Table 1](#pone.0120189.t001){ref-type="table"}). When taking into account all three bias categories for the analyses of adjusted survival outcomes, the quality scores ranged from 111.5 (18.6% of maximum) to 576 (86% of maximum); 36 studies (55%) were considered HQ with scores \>300 ([Fig. 2B](#pone.0120189.g002){ref-type="fig"} and [Table 1](#pone.0120189.t001){ref-type="table"}). For both unadjusted and adjusted outcomes the 'Unselected cohort studies' had the highest scores (*P* \<0.001 and 0.001, respectively; [Fig. 2A and B](#pone.0120189.g002){ref-type="fig"}).

![Quality distribution based on selection bias, misclassification bias and confounding/accounting for mediating variables in all included studies (n = 66).\
The scores for selection bias and misclassification bias were taken into account for the analysis of the univariate outcomes (panel A). The scores for selection bias, misclassification bias and confounding accounting for mediating variables were taken into account for the analysis of multivariate outcomes (panel B). *CGC based studies with ext*. *ref*. = *CGC based studies with external reference group; CGC based studies with int*. *ref*. = *CGC based studies with internal reference group*.](pone.0120189.g002){#pone.0120189.g002}

[S3 Supporting Information](#pone.0120189.s003){ref-type="supplementary-material"} shows the number of studies reporting risk estimates for the specific outcomes per mutation type. The mutation types and outcomes reported per study varied greatly; only for 15 risk estimates out of 48, more than four HQ studies were available.

*BRCA1* and *BRCA2* mutation carriership and survival {#sec012}
-----------------------------------------------------

In the following paragraphs we provided summaries of the results of the different survival outcomes for *BRCA1* and *BRCA2* carriers. Extensive descriptions of the reported results are available in the Supporting information as indicated.

### *BRCA1* mutation carriership and overall survival. {#sec013}

The forest plots of absolute survival differences in [Fig. 3A](#pone.0120189.g003){ref-type="fig"} and HRs in [Fig. 3B](#pone.0120189.g003){ref-type="fig"} showed inconsistent results for both the HQ studies as well the other studies ([S4 Supporting Information](#pone.0120189.s004){ref-type="supplementary-material"}, part A). Nevertheless, all unadjusted pooled estimates showed a worse survival for *BRCA1* mutation carriers, though effects were small: pooled 10-year absolute survival difference 4.9%; pooled HR 1.17 (95% CI 0.93--1.40) ([Table 3](#pone.0120189.t003){ref-type="table"} and [S6 Supporting Information](#pone.0120189.s006){ref-type="supplementary-material"}, panel A). Also the pooled estimate of the adjusted HR of 1.14 (95% CI 0.73--1.55) indicated a small survival disadvantage for *BRCA1* mutation carriers, but the heterogeneity test showed a large inconsistency between the results reported ([Table 3](#pone.0120189.t003){ref-type="table"} and [S6 Supporting Information](#pone.0120189.s006){ref-type="supplementary-material"}, panel B). Using the best-evidence synthesis, we concluded that there is still indecisive evidence for an association between *BRCA1* mutation carriership and unadjusted/adjusted overall survival of breast cancer patients ([Table 4](#pone.0120189.t004){ref-type="table"}).

![Forest plots of studies reporting survival estimates for *BRCA1* mutation carriers compared to 'non-carriers', classified per study type and sorted by quality score.\
Separate forest plots are shown of studies reporting overall survival (panels A and B), breast cancer-specific survival (panels C and D), metastasis-free survival (panels E and F) and recurrence-free survival (panel G) of *BRCA1* mutation carriers compared to 'non-carriers'. Additionally, the results for each type of survival outcome are stratified per reported risk estimate: the 5-year and 10-year absolute overall survival difference (panels A, C, E, G) and the adjusted and unadjusted hazard ratios for overall survival (panels B, D, F). *Size of the bullet represents the number of included carriers; black bullet = HQ study; round bullet (●) and \* = A*. *Jewish study population*, *only founder mutations tested; square bullet (■) and \*\* = specific study population (but not A*. *Jewish)*, *in which only founder mutations were tested;--- = 95% Confidence interval (only for hazard ratios); CGC based studies with ext*. *ref*. = *CGC based studies with external reference group; CGC based studies with int*. *ref*. = *CGC based studies with internal reference group; Sign = statistically significant (P \< 0*.*05); NS = not statistically significant; NR = not reported; †Adjusted for clinico-pathological characteristics and/or treatment*.](pone.0120189.g003){#pone.0120189.g003}

10.1371/journal.pone.0120189.t003

###### Pooled estimates and heterogeneity analysis for separate risk estimates.

![](pone.0120189.t003){#pone.0120189.t003g}

                                                                                                                                                                                                                                                                                            Heterogeneity analysis   
  ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------ ------------ ------- ------------------------ ----
  ***BRCA1* mutation carriers compared to 'non-carriers'**                                                                                                                                                                                                                                                           
  Overall                                                                            Unadjusted                                                                         5-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   15           -3.3         NA      NA                       NA
  10-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   12                                                                                 -4.9                                                                              NA           NA           NA                               
  Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               6                                                                                  1.17                                                                              0.93--1.40   3.59         0.61                             
  Adjusted                                                                           Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               11                                                                                1.14         0.73--1.55   42.79   \<0.001                  
  BC-specific                                                                        Unadjusted                                                                         5-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   4            -6.2         NA      NA                       NA
  10-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   6                                                                                  -6.8                                                                              NA           NA           NA                               
  Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               3                                                                                  1.12                                                                              0.71--1.53   1.86         0.40                             
  Adjusted                                                                           Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               5                                                                                 0.92         0.58--1.26   6.18    0.19                     
  Metastasis-free                                                                    Unadjusted                                                                         5-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   3            -5.4         NA      NA                       NA
  10-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   2                                                                                  -4.7                                                                              NA           NA           NA                               
  Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               3                                                                                  1.09                                                                              0.54--1.65   2.90         0.24                             
  Adjusted                                                                           Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               6                                                                                 0.99         0.63--1.43   6.30    0.28                     
  Recurrence-free                                                                    Unadjusted                                                                         5-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   6            -10.7        NA      NA                       NA
  10-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   3                                                                                  -9.5                                                                              NA           NA           NA                               
  Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               No HQ studies available                                                                                                                                                                                                         
  ***BRCA2* mutation carriers compared to 'non-carriers'**                                                                                                                                                                                                                                                           
  Overall                                                                            Unadjusted                                                                         5-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   9            -4.4         NA      NA                       NA
                                                                                     10-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   7                                                                                 -2           NA           NA      NA                       
                                                                                     Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               3                                                                                 1.09         0.58--1.59   5.22    0.07                     
  BC-specific                                                                        Unadjusted                                                                         5-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   2            -4.3         NA      NA                       NA
  10-year absolute survival difference (%)[^*a*^](#t003fn002){ref-type="table-fn"}   4                                                                                  -14.8                                                                             NA           NA           NA                               
  Hazard ratio[^*b*^](#t003fn003){ref-type="table-fn"}                               2                                                                                  1.57                                                                              1.29--1.86   0.27         0.60                             

The risk estimates which are shown are from outcomes for which more than four high quality studies were available and evidence could be formed using the best-evidence synthesis ([Table 4](#pone.0120189.t004){ref-type="table"} and [Table 5](#pone.0120189.t005){ref-type="table"}). Only high quality (HQ) studies are considered.

^*a*^ *No heterogeneity analysis performed*. *Pooling weighted on the number of included BRCA1 or BRCA2 mutation carriers ((weight per study (%) = (n of carriers in that specific study / total n of carriers of all studies which are used to form the pooled estimate)\*100));*

^*b*^ *Random effect (DerSimonian and Laird) analyses performed;*

^*c*^ *Results of the heterogeneity test of the random effect (DerSimonian and Laird) analyses*.

10.1371/journal.pone.0120189.t004

###### Best-evidence synthesis: a summary of the available evidence for the relation between *BRCA1* mutation carriership and breast cancer prognosis.

![](pone.0120189.t004){#pone.0120189.t004g}

  Type of survival   Unadjusted/ adjusted[^a^](#t004fn002){ref-type="table-fn"}   Studies reporting a worse survival[^b^](#t004fn003){ref-type="table-fn"} % (n / total n)   Studies reporting a better survival[^c^](#t004fn004){ref-type="table-fn"} % (n / total n)   Evidence[^d^](#t004fn005){ref-type="table-fn"} (based on all studies)   Evidence[^d^](#t004fn005){ref-type="table-fn"} (based on HQ studies)                                                     
  ------------------ ------------------------------------------------------------ ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------- ----------------
  Overall            Unadjusted                                                   47 (8/17)                                                                                  **41 (7/17)**                                                                               18 (3/17)                                                               **18 (3/17)**                                                          Indecisive                                        **Indecisive**
  Adjusted           67 (2/3)                                                     **55 (6/11)**                                                                              33 (1/3)                                                                                    **18 (2/11)**                                                           Indecisive                                                             **Indecisive**                                    
  BC-specific        Unadjusted                                                   33 (2/6)                                                                                   **43 (3/7)**                                                                                17 (1/6)                                                                **14 (1/7)**                                                           Nil                                               **Indecisive**
  Adjusted           0 (0/1)                                                      **40 (2/5)**                                                                               100 (1/1)                                                                                   **60 (3/5)**                                                            Nil                                                                    **Indecisive**                                    
  Metastasis-free    Unadjusted                                                   25 (1/4)                                                                                   **75 (3/4)**                                                                                50 (2/4)                                                                **25 (1/4)**                                                           Indecisive                                        **Indecisive**
  Adjusted           0 (0/1)                                                      **67 (4/6)**                                                                               0 (0/1)                                                                                     **33 (2/6)**                                                            Indecisive                                                             **Indecisive**                                    
  Recurrence-free    Unadjusted                                                   11 (1/9)                                                                                   **67 (4/6)**                                                                                11 (1/9)                                                                **17 (1/6)**                                                           Nil                                               **Moderate**
  Adjusted           0 (0/1)                                                      0 (0/1)                                                                                    0 (0/1)                                                                                     100 (1/1)                                                               Indecisive[\*](#t004fn006){ref-type="table-fn"}                        Indecisive[\*](#t004fn006){ref-type="table-fn"}   

Studies are taken into account reporting the 5-year absolute survival and/or 10-year absolute survival and/or unadjusted hazard ratio (for univariate outcomes) or reporting a multivariate hazard ratio (for multivariate outcomes).

^*a*^ *Adjusted survival is based on risk estimates adjusted for clinico-pathological characteristics and/or treatment;*

^*b*^ *Worse survival for univariate (unadjusted) outcomes*: *unadjusted HR \> = 1*.*14 or 5-year absolute survival difference \> = 10% or 10-year absolute survival difference \> = 10% (when the 5 and 10 year survival differences go in opposite directions*, *we decided there was no difference in survival)*. *Worse survival for multivariate (adjusted) outcomes*: *adjusted HR \> = 1*.*14;*

^*c*^ *Better survival for univariate (unadjusted) outcomes*: *unadjusted HR \< = 0*.*88 or 5-year absolute survival difference \> = 10% or 10-year absolute survival difference \> = 10% (when the 5 and 10 year survival differences go in opposite directions*, *we decided there was no difference in survival)*. *Better survival for multivariate (adjusted) outcomes*: *adjusted HR \< = 0*.*88;*

^*d*^ *See appendix p 3 (Best-evidence synthesis)*. *Strong evidence*: *more than 75% of the HQ studies reported a worse survival; moderate evidence*: *60--75% of the HQ studies reported a worse survival and less than 25% of the HQ studies reported a better survival / 50--60% of the HQ studies reported a worse survival and less than 10% of the HQ studies reported a better survival; nil evidence*: *more than 60% of the HQ studies reported a better survival or no association / more than 40% of the HQ studies reported a better survival;*

*indecisive e evidence*: *all other options / less than four HQ studies available (\*)*.

10.1371/journal.pone.0120189.t005

###### Best-evidence synthesis: a summary of the available evidence for the relation between *BRCA2* mutation carriership and breast cancer prognosis.

![](pone.0120189.t005){#pone.0120189.t005g}

  Type of survival   Unadjusted/ adjusted[^a^](#t005fn002){ref-type="table-fn"}   Studies reporting a worse survival[^b^](#t005fn003){ref-type="table-fn"} % (n / total n)   Studies reporting a better survival[^c^](#t005fn004){ref-type="table-fn"} % (n / total n)   Evidence[^d^](#t005fn005){ref-type="table-fn"} (based on all studies)   Evidence[^d^](#t005fn005){ref-type="table-fn"} (based on HQ studies)                                                     
  ------------------ ------------------------------------------------------------ ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  Overall            Unadjusted                                                   14 (1/7)                                                                                   **50 (5/10)**                                                                               14 (1/7)                                                                **20 (2/10)**                                                          Nil                                               **Indecisive**
  Adjusted           0 (0/3)                                                      33 (1/3)                                                                                   100 (3/3)                                                                                   0 (0/3)                                                                 Nil                                                                    Indecisive[\*](#t005fn006){ref-type="table-fn"}   
  BC-specific        Unadjusted                                                   33 (2/6)                                                                                   **50 (2/4)**                                                                                0 (0/6)                                                                 **25 (1/4)**                                                           Indecisive                                        **Indecisive**
  Adjusted           100 (2/2)                                                    33 (1/3)                                                                                   0 (0/2)                                                                                     33 (1/3)                                                                Indecisive                                                             Indecisive[\*](#t005fn006){ref-type="table-fn"}   
  Metastasis-free    Unadjusted                                                   0 (0/2)                                                                                    100 (1/1)                                                                                   50 (1/2)                                                                0 (0/1)                                                                Indecisive[\*](#t005fn006){ref-type="table-fn"}   Indecisive[\*](#t005fn006){ref-type="table-fn"}
  Adjusted           NA                                                           0 (0/2)                                                                                    NA                                                                                          50 (1/2)                                                                Indecisive[\*](#t005fn006){ref-type="table-fn"}                        Indecisive[\*](#t005fn006){ref-type="table-fn"}   
  Recurrence-free    Unadjusted                                                   0 (0/4)                                                                                    0 (0/1)                                                                                     25 (1/4)                                                                0 (0/1)                                                                Nil                                               Indecisive[\*](#t005fn006){ref-type="table-fn"}
  Adjusted           0 (0/1)                                                      0 (0/1)                                                                                    100 (1/1)                                                                                   100 (1/1)                                                               Indecisive[\*](#t005fn006){ref-type="table-fn"}                        Indecisive[\*](#t005fn006){ref-type="table-fn"}   

Studies are taken into account reporting the 5-year absolute survival and/or 10-year absolute survival and/or unadjusted hazard ratio (for univariate outcomes) or reporting a multivariate hazard ratio (for multivariate outcomes).

^*a*^ *Adjusted survival is based on risk estimates adjusted for clinico-pathological characteristics and/or treatment;*

^*b*^ *Worse survival for univariate (unadjusted) outcomes*: *unadjusted HR \> = 1*.*14 or 5-year absolute survival difference \> = 10% or 10-year absolute survival difference \> = 10% (when the 5 and 10 year survival differences go in opposite directions*, *we decided there was no difference in survival)*. *Worse survival for multivariate (adjusted) outcomes*: *adjusted HR \> = 1*.*14;*

^*c*^ *Better survival for univariate (unadjusted) outcomes*: *unadjusted HR \< = 0*.*88 or 5-year absolute survival difference \> = 10% or 10-year absolute survival difference \> = 10% (when the 5 and 10 year survival differences go in opposite directions*, *we decided there was no difference in survival)*. *Better survival for multivariate (adjusted) outcomes*: *adjusted HR \< = 0*.*88;*

^*d*^ *See appendix p 3 (Best-evidence synthesis)*. *Strong evidence*: *more than 75% of the HQ studies reported a worse survival; moderate evidence*: *60--75% of the HQ studies reported a worse survival and less than 25% of the HQ studies reported a better survival / 50--60% of the HQ studies reported a worse survival and less than 10% of the HQ studies reported a better survival; nil evidence*: *more than 60% of the HQ studies reported a better survival or no association / more than 40% of the HQ studies reported a better survival;*

*indecisive e evidence*: *all other options / less than four HQ studies available (\*)*.

### *BRCA1* mutation carriership and breast cancer-specific survival {#sec014}

The forest plots in [Fig. 3C](#pone.0120189.g003){ref-type="fig"} (absolute survival differences) and [Fig. 3D](#pone.0120189.g003){ref-type="fig"} (HRs) seemed to point to a worse unadjusted breast cancer-specific survival for *BRCA1* compared to 'non-carriers', especially when looking at the HQ studies, although these effects were generally small ([S4 Supporting Information](#pone.0120189.s004){ref-type="supplementary-material"}, part B). The pooled breast cancer-specific survival estimates were a 10-year absolute worse difference of 6.8% and a HR of 1.12 (95% CI 0.71--1.53); in contrast, the adjusted HR showed a slightly better breast cancer-specific survival for *BRCA1* mutation carriers (0.92, 95% CI 0.58--1.36). None of the pooled estimates were statistically significant ([Table 3](#pone.0120189.t003){ref-type="table"} and [S6](#pone.0120189.s006){ref-type="supplementary-material"} Supporting Information, panels C and D). Using the best-evidence synthesis, we concluded there is indecisive evidence for an association between *BRCA1* mutation carriership and unadjusted/adjusted breast cancer-specific survival ([Table 4](#pone.0120189.t004){ref-type="table"}).

### *BRCA1* mutation carriership and metastasis-free survival {#sec015}

The forest plots of absolute survival differences in [Fig. 3E](#pone.0120189.g003){ref-type="fig"} and HRs in [Fig. 3F](#pone.0120189.g003){ref-type="fig"} showed inconsistent results for both the HQ and other studies ([S4 Supporting Information](#pone.0120189.s004){ref-type="supplementary-material"}, part C). The pooled estimates showed a small unadjusted metastasis-free survival difference for *BRCA1* compared to the 'non-carriers': around 5% worse survival and a pooled HR of 1.09 (95% CI 0.54--1.65); while the pooled adjusted HR was 0.99 (95% CI 0.63--1.43) ([Table 3](#pone.0120189.t003){ref-type="table"} and [S6 Supporting Information](#pone.0120189.s006){ref-type="supplementary-material"}, panels E and F). Due to the inconsistency in the results, the best-evidence synthesis showed there is indecisive evidence for a conclusion about the association between *BRCA1* carriership and metastasis-free survival ([Table 4](#pone.0120189.t004){ref-type="table"}).

### *BRCA1* mutation carriership and recurrence-free survival {#sec016}

Most of the studies, certainly when considering the HQ studies, reported a worse unadjusted absolute recurrence-free survival for *BRCA1* mutation carriers compared to 'non-carriers' (forest plot: [Fig. 3G](#pone.0120189.g003){ref-type="fig"}; [S4 Supporting Information](#pone.0120189.s004){ref-type="supplementary-material"}, part D). This worse survival was supported by pooling of the study results: 10% absolute survival difference between the *BRCA1* and 'non-carriers' ([Table 3](#pone.0120189.t003){ref-type="table"}). The best-evidence synthesis also showed there was moderate evidence for a worse unadjusted recurrence-free survival for *BRCA1* compared to 'non-carriers' ([Table 4](#pone.0120189.t004){ref-type="table"}). Adjusted HRs for recurrence-free survival were only reported in two studies ([S4 Supporting Information](#pone.0120189.s004){ref-type="supplementary-material"}, part D) and no conclusions could be drawn.

### *BRCA2* mutation carriership and overall survival {#sec017}

Although the forest plots of absolute survival differences in [Fig. 4A](#pone.0120189.g004){ref-type="fig"} and HRs in [Fig. 4B](#pone.0120189.g004){ref-type="fig"} showed a tendency towards worse unadjusted overall survival for *BRCA2* mutation carriers compared to 'non-carriers', the absolute survival differences were small, mostly below 10%, and the results were inconsistent, certainly among the HQ studies ([S5 Supporting Information](#pone.0120189.s005){ref-type="supplementary-material"}, part A). The pooled estimates showed only a small overall survival difference between *BRCA2* carriers and 'non-carriers': 2% 10-year worse survival and a pooled HR of 1.09 (95% CI 0.58--1.59); with a suggestion for statistical heterogeneity between the results (*P* = 0.07; [Table 3](#pone.0120189.t003){ref-type="table"} and [S6](#pone.0120189.s006){ref-type="supplementary-material"} Supporting Information, panel G). Using the best-evidence synthesis, there was indecisive evidence for an association between *BRCA2* mutation carriership and unadjusted overall survival of breast cancer patients. Although the HQ studies reporting an adjusted HR (n = 3) found worse adjusted overall survival for *BRCA2* compared to 'non-carriers' ([Fig. 4B](#pone.0120189.g004){ref-type="fig"}), with our criteria there was insufficient evidence for a conclusion ([Table 5](#pone.0120189.t005){ref-type="table"}).

![Forest plots of studies reporting survival estimates for *BRCA2* mutation carriers compared to 'non-carriers', classified per study type and sorted by quality score.\
Separate forest plots are shown of studies reporting overall survival (panels A and B), breast cancer-specific survival (panels C and D) of *BRCA2* mutation carriers compared to 'non-carriers'. Additionally, the results for each type of survival outcome are stratified per reported risk estimate: the 5-year and 10-year absolute overall survival difference (panels A and C) and the adjusted and unadjusted hazard ratios for overall survival (panels B and D). *Size of the bullet represents the number of included carriers; black bullet = HQ study; round bullet (●) and \* = A*. *Jewish study population*, *only founder mutations tested; square bullet (■) and \*\* = specific study population (but not A*. *Jewish)*, *in which only founder mutations were tested; --- = 95% Confidence interval (only for hazard ratios); CGC based studies with ext*. *ref*. = *CGC based studies with external reference group; CGC based studies with int*. *ref*. = *CGC based studies with internal reference group; Sign = statistically significant (P \< 0*.*05); NS = not statistically significant; NR = not reported; †Adjusted for clinico-pathological characteristics and/or treatment*.](pone.0120189.g004){#pone.0120189.g004}

### *BRCA2* mutation carriership and breast cancer-specific survival {#sec018}

Based on the forest plots of absolute survival differences in [Fig. 4C](#pone.0120189.g004){ref-type="fig"} and HRs in [Fig. 4D](#pone.0120189.g004){ref-type="fig"} there seemed to be more studies reporting a worse breast cancer-specific survival for *BRCA2* compared to 'non-carriers' than studies reporting a better breast cancer-specific survival ([S5 Supporting Information](#pone.0120189.s005){ref-type="supplementary-material"}, part B). This worse survival was also supported by the pooled analyses, showing a 10-year absolute survival difference between the *BRCA2* and 'non-carriers' of about 15% ([Table 3](#pone.0120189.t003){ref-type="table"}). The pooled, significant, unadjusted HR was 1.57 (95% CI 1.29--1.86) ([Table 3](#pone.0120189.t003){ref-type="table"} and [S6](#pone.0120189.s006){ref-type="supplementary-material"} Supporting Information, panel H). This survival difference seemed to be driven by one large study \[[@pone.0120189.ref062]\], and, when using the best-evidence synthesis, the evidence was still judged to be indecisive. For adjusted breast cancer-specific survival too few HQ studies were available ([Fig. 4D](#pone.0120189.g004){ref-type="fig"}) and no conclusion could be drawn using the best-evidence synthesis ([Table 5](#pone.0120189.t005){ref-type="table"}).

### *BRCA2* mutation carriership and metastasis-free survival {#sec019}

There were only three studies \[[@pone.0120189.ref020],[@pone.0120189.ref035]\] that determined the association between *BRCA2* mutation carriership and metastasis-free survival; the studies reported conflicting results ([S5 Supporting Information](#pone.0120189.s005){ref-type="supplementary-material"}, part C). Also, there were not enough HQ studies available to provide conclusive evidence using the best-evidence synthesis for an association between *BRCA2* mutation carriership and unadjusted/adjusted metastasis-free survival of breast cancer patients ([Table 5](#pone.0120189.t005){ref-type="table"}).

### *BRCA2* mutation carriership and recurrence-free survival {#sec020}

The five studies \[[@pone.0120189.ref017],[@pone.0120189.ref020],[@pone.0120189.ref028],[@pone.0120189.ref058]\] which determined the association between *BRCA2* mutation carriership and recurrence-free survival reported inconsistent results ([S5 Supporting Information](#pone.0120189.s005){ref-type="supplementary-material"}, part D). Hence using the best-evidence synthesis there were not enough HQ studies available to provide conclusive evidence about the association between *BRCA2* mutation carriership and recurrence-free survival of breast cancer patients ([Table 5](#pone.0120189.t005){ref-type="table"}).

### *BRCA1* and *BRCA2* mutation carriership combined and survival {#sec021}

Though the focus of our review was to determine the association between breast cancer prognosis and carriership of the *BRCA1* and *BRCA2* mutations separately, there were many studies combining both groups in their analyses ([S7 Supporting Information](#pone.0120189.s007){ref-type="supplementary-material"}). Using the best-evidence synthesis for *BRCA1* and *BRCA2* mutation carriers combined ([S7 Supporting Information](#pone.0120189.s007){ref-type="supplementary-material"}, part E), for most of the unadjusted survival outcomes with sufficient HQ studies available, there was indecisive evidence because of the large heterogeneity of the results. Only for the association between *BRCA1/2* carriership and unadjusted overall survival there was nil evidence, implying no association. For all the adjusted outcomes less than four HQ studies were available and therefore no evidence could be provided.

Sensitivity analysis {#sec022}
--------------------

When using the best-evidence synthesis on all studies, irrespective of study quality, evidence remained indecisive for most outcomes or changed to nil ([Table 4](#pone.0120189.t004){ref-type="table"} and [Table 5](#pone.0120189.t005){ref-type="table"}). When using only the unselected cohort studies (mostly HQ) for the best-evidence synthesis, for most outcomes evidence remained indecisive; however, there was moderate evidence for a worse unadjusted and adjusted overall survival for *BRCA1* mutation carriers compared to non-carriers ([S8 Supporting Information](#pone.0120189.s008){ref-type="supplementary-material"}). In the sensitivity analyses with all studies and the 'unselected cohort studies' the moderate evidence for a worse recurrence-free survival for *BRCA1* mutation carriers changed to nil and indecisive respectively.

[S9 Supporting Information](#pone.0120189.s009){ref-type="supplementary-material"} shows a summary of all other sensitivity analyses performed for the best-evidence synthesis. When the absolute survival and HR cut-offs in the best-evidence synthesis were less stringent (than the 10% absolute difference or HRs ≤0.88 or ≥1.14), the evidence for a worse survival for *BRCA1* and/or *BRCA2* compared to 'non-carriers' became stronger for most of the outcomes, i.e. from indecisive to moderate evidence, or remained the same. With more stringent cut-offs, the evidence became weaker for most of the outcomes, i.e. from indecisive to nil evidence, or remained the same. Only for the association between *BRCA1* carriership and unadjusted (worse) recurrence-free survival the moderate evidence held in all the sensitivity analyses. In the sensitivity analysis where only the statistically significant associations were considered, the evidence changed for most outcomes; mostly from indecisive to nil evidence.

Effects of confounders/mediating factors on the association between BRCA1 and BRCA2 mutation carriership and prognosis {#sec023}
----------------------------------------------------------------------------------------------------------------------

It is already known that breast cancers in carriers of *BRCA1* mutations exhibit different pathological characteristics compared to tumours in non-carriers, leading to treatment differences \[[@pone.0120189.ref002],[@pone.0120189.ref003]\]. Also in the studies included in this review, there were many differences reported in tumour characteristics between *BRCA1* and also *BRCA2* mutation carriers compared to 'non-carriers' ([S10 Supporting Information](#pone.0120189.s010){ref-type="supplementary-material"}, part A). Only 32 studies reported HRs adjusted for tumour characteristics and/or treatment ([Table 2](#pone.0120189.t002){ref-type="table"}).

To examine the effect of adjustment for confounders on the prognosis of *BRCA1* and *BRCA2* mutation carriers, we compared pairs of an unadjusted HR (HRunadjusted) and adjusted HR (HRadjusted). In general, the associations between *BRCA1/2* carriership and survival became less strong after adjustment for confounders, especially when the unadjusted results showed a worse survival for the carriers ([Table 6](#pone.0120189.t006){ref-type="table"}; [S10 Supporting Information](#pone.0120189.s010){ref-type="supplementary-material"}, part B).

10.1371/journal.pone.0120189.t006

###### Table of studies reporting an unadjusted and adjusted hazard ratio.

![](pone.0120189.t006){#pone.0120189.t006g}

  Mutation                Out-come                   Authors + year             Study type                 \% of max QS   HR[^a^](#t006fn003){ref-type="table-fn"}   95% CI       HR[^b^](#t006fn004){ref-type="table-fn"}   95% CI                                 Unadjusted survival carriers compared to 'non-carriers'?[^c^](#t006fn006){ref-type="table-fn"}   Direction of the difference adjusted vs. unadjusted survival   HR adjusted for:                           
  ----------------------- -------------------------- -------------------------- -------------------------- -------------- ------------------------------------------ ------------ ------------------------------------------ -------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ------------------ ----- ----- --- --- --- --
  BRCA1                   OS                         Verhoog (1998)             CGC based with ext. ref.   42             **1.04**                                   0.63--1.71   **1.21**                                   0.72--2.04                             Worse                                                                                            [↑](#t006fn007){ref-type="table-fn"}                                              x                       
  Brekelmans (2007)       CGC based with ext. ref.   52                         **1.01**                   0.75--1.37     **1.3**                                    0.91--1.85   Worse                                      [↑](#t006fn007){ref-type="table-fn"}   x                                                                                                x                                                                                             x   x       
  Lee (2011)              CGC based with int. ref.   47                         **0.64**                   0.27--1.37     **0.73**                                   NR           Better                                     [=](#t006fn006){ref-type="table-fn"}                                                                                                    x                                                                                                         
  Stoppa-Lyonnet (2000)   CGC based with int. ref.   52                         **5.1**                    NR             **3.5**                                    1.3--9.7     Worse                                      [↓](#t006fn008){ref-type="table-fn"}                                                                                                                                                                                      *x*                     
  Goodwin (2012)          CGC based with int. ref.   76                         **1.43**                   0.91--2.23     **0.99**                                   0.62--1.59   Worse                                      [↔](#t006fn009){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  Bonadona (2007)         Unselected cohort          69                         **0.67**                   0.16--2.77     **0.29**                                   0.04--2.26   Better                                     [↑](#t006fn007){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  Goode (2002)            Unselected cohort          72                         **4.14**                   1.32--13       **1.99**                                   0.47--8.45   Worse                                      [↓](#t006fn008){ref-type="table-fn"}   x                                                                                                                                                                                                          
  Huzarski (2013)         Unselected cohort          82                         **1.13**                   0.83--1.57     **1.81**                                   1.26--2.61   Worse                                      [↑](#t006fn007){ref-type="table-fn"}   x                                                                                                                                                                                  *x*   *x*   x   x       
  Goffin (2003)           Unselected cohort          82                         **1.9**                    0.99--3.6      **1.4**                                    0.7--2.9     Worse                                      [↓](#t006fn008){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*                     
  Rennert (2007)          Unselected cohort          90                         **1.09**                   0.79--1.51     **1.13**                                   0.78--1.66   Worse                                      [=](#t006fn006){ref-type="table-fn"}                                                                                                                                                                   *x*                *x*   *x*               
  BCSS                    Brekelmans (2007)          CGC based with ext. ref.   52                         **0.89**       0.63--1.25                                 **1.21**     0.83--1.76                                 Better                                 [↔](#t006fn009){ref-type="table-fn"}                                                             x                                                              x                                  x   x   
  Lee (2011)              CGC based with int. ref.   47                         **0.58**                   0.25--1.25     **0.73**                                   NR           Better                                     [↓](#t006fn008){ref-type="table-fn"}                                                                                                    x                                                                                                         
  Bonadona (2007)         Unselected cohort          69                         **0.67**                   0.16--2.77     **0.29**                                   0.04--2.26   Better                                     [↑](#t006fn007){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  Rennert (2007)          Unselected cohort          90                         **1.08**                   0.72--1.63     **0.76**                                   0.45--1.3    Worse                                      [↔](#t006fn009){ref-type="table-fn"}                                                                                                                                                                                      *x*   *x*               
  Chappuis (2005)         Unselected cohort          96                         **1.9**                    0.99--3.6      **0.8**                                    0.4--1.6     Worse                                      [↔](#t006fn009){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  RFS                     Verhoog (1998)             CGC based with ext. ref.   42                         **1**          0.65--1.55                                 **1.09**     0.7--1.7                                   Equal                                  [=](#t006fn006){ref-type="table-fn"}                                                                                                                            x                                          
  Brekelmans (2007)       CGC based with ext. ref.   52                         **0.92**                   0.56--1.51     **0.84**                                   0.41--1.75   Better                                     [=](#t006fn006){ref-type="table-fn"}   x                                                                                                x                                                                                             x   x       
  MFS                     Brekelmans (2007)          CGC based with ext. ref.   52                         **0.71**       0.52--0.96                                 **1.25**     0.87--1.92                                 Better                                 [↔](#t006fn009){ref-type="table-fn"}                                                             x                                                              x                                  x   x   
  Lee (2011)              CGC based with int. ref.   47                         **0.79**                   0.38--1.58     **0.9**                                    NR           Better                                     [↓](#t006fn008){ref-type="table-fn"}                                                                                                    x                                                                                                         
  Stoppa-Lyonnet (2000)   CGC based with int. ref.   52                         **3.5**                    NR             **2.6**                                    1--6.5       Worse                                      [↓](#t006fn008){ref-type="table-fn"}                                                                                                                                                                                      *x*         x           
  Goodwin (2012)          CGC based with int. ref.   76                         **1.19**                   0.74--1.89     **0.83**                                   0.51--1.35   Worse                                      [↔](#t006fn009){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  Bonadona (2007)         Unselected cohort          69                         **0.47**                   0.12--1.94     **0.24**                                   0.03--1.82   Better                                     [↑](#t006fn007){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  Goffin (2003)           Unselected cohort          82                         **1.6**                    0.9--2.9       **1.2**                                    0.7--2.4     Worse                                      [↓](#t006fn008){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*                     
  BRCA2                   OS                         Verhoog (1999)             CGC based with ext. ref.   46             **0.75**                                   0.37--1.51   **0.59**                                   0.27--1.59                             Better                                                                                           [↑](#t006fn007){ref-type="table-fn"}                                              x                       
  Goodwin (2012)          CGC based with int. ref.   76                         **1.81**                   1.15--2.86     **1.12**                                   0.7--1.79    Worse                                      [↓](#t006fn008){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*         x           
  Budroni (2009)          Unselected cohort          48                         **0.7**                    0.46--1.36     **0.8**                                    0.48--1.62   Better                                     [=](#t006fn006){ref-type="table-fn"}                                                                                                    x                                                                                                         
  Rennert (2007)          Unselected cohort          90                         **1.07**                   0.73--1.58     **1.2**                                    0.77--1.86   Worse                                      [↑](#t006fn007){ref-type="table-fn"}                                                                                                                                                                   *x*                *x*   *x*               
  BCSS                    Loman (2000)               CGC based with ext. ref.   36                         **2**          1.2--3.4                                   **1.6**      0.85--3.1                                  Worse                                  [↓](#t006fn008){ref-type="table-fn"}                                                                                                                            x                                          
  Heikkinen (2009)        CGC based with ext. ref.   42                         **2.34**                   1.5--3.66      **2.06**                                   1.03--4.15   Worse                                      [↓](#t006fn008){ref-type="table-fn"}   x                                                                                                                                                               *x*                *x*   *x*               
  Tryggvadottir (2013)    Unselected cohort          76                         **1.61**                   1.32--1.96     **0.98**                                   0.64--1.48   Worse                                      [↔](#t006fn009){ref-type="table-fn"}   x                                                                                                                                                                                  *x*   *x*   x           
  Rennert (2007)          Unselected cohort          90                         **1.42**                   0.92--2.19     **1.31**                                   0.8--2.15    Worse                                      [↓](#t006fn008){ref-type="table-fn"}                                                                                                                                                                   *x*                *x*   *x*               
  RFS                     Verhoog (1999)             CGC based with ext. ref.   46                         **0.92**       0.52--1.62                                 **0.84**     0.44--1.63                                 Better                                 [=](#t006fn006){ref-type="table-fn"}                                                                                                                            x                                          
  MFS                     Goodwin (2012)             CGC based with int. ref.   76                         **1.63**       1.02--2.6                                  **1**        0.62--1.61                                 Worse                                  [↓](#t006fn008){ref-type="table-fn"}                                                             x                                                                                 *x*   *x*       x       

The results are sorted on the mutation and survival outcome studied, and on the quality score of the study.

*OS = overall survival*; *BCSS = breast cancer-specific survival; RFS = recurrence-free survival; MFS = metastasis-free survival; CGC based with ext*. *ref*. = *CGC based study with external reference group; CGC based with int*. *ref*. = *CGC based study with internal reference group; Unselected cohort = Unselected cohort study;*

^*a*^ *Unadjusted Hazard ratio;*

^*b*^ *Adjusted Hazard ratio;*

^*c*^ *Definition of a better survival = HR \< 1*.*00; definition of a worse survival = HR \> 1*.*00;*

= *no difference (difference \< 0*.*1) between the effects;*

*↑ effect in the same direction but stronger (difference \> 0*.*1);*

*↓ effect in the same direction but weaker (difference \> 0*.*1);*

*↔ effects in the opposite direction*.

Only in four studies \[[@pone.0120189.ref011],[@pone.0120189.ref020],[@pone.0120189.ref047],[@pone.0120189.ref063]\] adjuvant treatment was considered as a confounder in the analyses ([Table 6](#pone.0120189.t006){ref-type="table"}) and in six studies \[[@pone.0120189.ref011],[@pone.0120189.ref031],[@pone.0120189.ref035],[@pone.0120189.ref049],[@pone.0120189.ref053],[@pone.0120189.ref063]\] analyses were stratified on chemotherapy (data not shown). In most studies a tendency towards a worse survival for *BRCA1* mutation carriers compared to 'non-carriers' was shown in the subgroup of patients not treated with adjuvant chemotherapy, and no difference in survival in those treated with chemotherapy. One study by Rennert and colleagues \[[@pone.0120189.ref049]\] reported a significant interaction between *BRCA1* status and chemotherapy (*P =* 0.02). Goodwin and colleagues \[[@pone.0120189.ref035]\] showed a worse outcome for *BRCA2* carriers compared to 'non-carriers' not treated with chemotherapy (HR 3.6, 95% CI 1.5--9.0). Only two studies \[[@pone.0120189.ref020],[@pone.0120189.ref063]\] took prophylactic surgery into account as an (time-varying) confounder in the analyses.

Exploring heterogeneity between the studies {#sec024}
-------------------------------------------

Based on the forest plots of all above results ([Fig. 3](#pone.0120189.g003){ref-type="fig"} and [Fig. 4](#pone.0120189.g004){ref-type="fig"}), there were indications for substantial heterogeneity between the studies. Using graphic analysis we determined the influence of the different types of bias on the heterogeneity ([S11 Supporting Information](#pone.0120189.s011){ref-type="supplementary-material"}) using the 5-year absolute difference and the adjusted HR for overall survival for *BRCA1* mutation carriers compared to 'non-carriers' since for these data most studies were available.

Studies with less misclassification bias appeared to more often report a worse survival for *BRCA1* mutation carriers compared to 'non-carriers', with stronger effects ([S11 Supporting Information](#pone.0120189.s011){ref-type="supplementary-material"}, panel C). This might be explained by a larger contrast between carriers and the 'non-carrier group' when all non-carriers are tested, a feature incorporated in the misclassification score. Within the item of selection bias the proportion of incident cases, but not study type, seemed to reduce the heterogeneity of the results ([S11 Supporting Information](#pone.0120189.s011){ref-type="supplementary-material"}, panels A and B). Unfortunately, duration and completeness of follow-up time were often not reported, so we could not assess the effect of these variables effect on the heterogeneity of the results. To see whether the extent of confounding in the studies explained the heterogeneity of the adjusted risk estimates, we graphically compared the adjusted HR to the percentage score of 'confounding/accounting for mediating variables' bias in the studies. From this graph a clear relation between the heterogeneity of the results and percentage of confounding was apparent, though due to the small number of studies it was difficult to draw firm conclusions ([S11 Supporting Information](#pone.0120189.s011){ref-type="supplementary-material"}, panel D).

Exploring publication bias {#sec025}
--------------------------

[S12 Supporting Information](#pone.0120189.s012){ref-type="supplementary-material"} shows the funnel plot for studies reporting the 5-year overall survival for *BRCA1* mutation carriers compared to 'non-carriers'. The funnel plot showed no clear evidence of publication bias.

Discussion {#sec026}
==========

Our review shows that, in contrast to currently held beliefs of many oncologists and despite 66 published studies, it is not yet possible to draw evidence-based conclusions about the association between *BRCA1* and/or *BRCA2* mutation carriership and breast cancer prognosis. We only found sufficient evidence for a 10% worse unadjusted recurrence-free survival for *BRCA1* mutation carriers. For all the other outcomes the evidence was judged to be indecisive. Although two less extensive reviews about *BRCA1* and *BRCA2* carriership and breast cancer-specific survival have been published \[[@pone.0120189.ref064],[@pone.0120189.ref065]\], this review is the first to use a systematic approach and standardized analysis, taking into account the methodological rigor of all the available studies, to arrive at the best evidence.

Despite the lack of evidence for a worse survival for *BRCA1* and *BRCA2* mutation carriers, we do see a tendency towards a survival disadvantage for all outcomes. E.g., although the best-evidence synthesis judged the evidence indecisive due to inconsistent findings and small effects, the pooled estimate shows a worse 10-year absolute breast cancer-specific survival difference of 14.8% for *BRCA2* carriers ([Table 3](#pone.0120189.t003){ref-type="table"}, [Fig. 3](#pone.0120189.g003){ref-type="fig"} and [Fig. 4](#pone.0120189.g004){ref-type="fig"}). Unfortunately, the large variation in the types of outcomes and the conflicting results reported between studies reduced the power for evidence-based conclusions for most of the outcomes. The most reported outcome was overall survival. However, we considered overall survival as the least relevant outcome because this is also affected by the increased ovarian cancer mortality in carriers; an issue that was rarely mentioned in the reviewed papers. The only outcome for which we found evidence that there was an association with *BRCA1* mutation carriership, i.e., unadjusted recurrence-free survival, is a heterogeneous survival measure with inconsistent definitions (often not even reported) across studies.

Considering that certain prognostically important clinico-pathological features are different for *BRCA1*-associated tumours ([S10 Supporting Information](#pone.0120189.s010){ref-type="supplementary-material"}, part A) \[[@pone.0120189.ref002],[@pone.0120189.ref003]\], a crucial question is to which extent *BRCA1/2* mutation carriership and the specific tumour features associated with carriership can be considered to be independent when studying prognosis. The heterogeneity of the reported results did not allow a conclusion regarding the contribution of *BRCA1/2* status and tumour features to a worse survival ([Fig. 3](#pone.0120189.g003){ref-type="fig"} and [Fig. 4](#pone.0120189.g004){ref-type="fig"}; [Table 4](#pone.0120189.t004){ref-type="table"} and [Table 5](#pone.0120189.t005){ref-type="table"}). However, individual and pooled adjusted HRs compared to unadjusted HRs often resulted in a shift to a relatively more favourable survival for both *BRCA1* and *BRCA2* mutation carriers compared to 'non-carriers' ([Table 3](#pone.0120189.t003){ref-type="table"} and [Table 6](#pone.0120189.t006){ref-type="table"}). Based on these results we can conclude that clinico-pathological characteristics of the tumour might indeed play a confounding or mediating role in the association between *BRCA1/2* mutation carriership and breast cancer survival, though more research should be performed to further elucidate this.

Primary breast cancer treatments may be different for *BRCA1* and *BRCA2* mutation carriers compared to non-carriers, mostly related to different pathological features of tumours in carriers ([S10 Supporting Information](#pone.0120189.s010){ref-type="supplementary-material"}, part A) \[[@pone.0120189.ref002],[@pone.0120189.ref003]\]. Although the data are scarce, our review supports what was earlier suggested by others \[[@pone.0120189.ref066]\], i.e. that that the therapy response of tumours in *BRCA1/2* mutation carriers might be better compared to that in non-carriers. Future studies should provide insight into the potential confounding or mediating role of treatment when examining survival of *BRCA1/2* mutation carriers.

To explain the large heterogeneity between the results reported in the included studies, we examined whether this was related to the extent of selection bias (largely dependent on whether incident cases were included and the type of comparison group used), the extent of misclassification bias (largely dependent on whether non-carriers were tested) and the amount of confounding bias in the different studies. Surprisingly, the only two factors that seem to explain part of the heterogeneity were misclassification bias; when a study had not tested the comparison ('non-carriers') group, and the proportion of incident cases ([S11 Supporting Information](#pone.0120189.s011){ref-type="supplementary-material"}, panels C and D). The sensitivity analysis of the best-evidence synthesis including only 'unselected cohort studies' indeed showed that the results altered when including only these type of studies ([S8 Supporting Information](#pone.0120189.s008){ref-type="supplementary-material"}). Furthermore, the other sensitivity analyses of the best-evidence synthesis ([S9 Supporting Information](#pone.0120189.s009){ref-type="supplementary-material"}) highlighted that the potential associations we are reviewing in this paper appear to be very weak (absolute differences around 5%). Moreover, it showed the lack of power in the individual studies; the already limited evidence from the best-evidence synthesis disappeared in the sensitivity analysis which only considered statistically significant results. Other reasons for the large heterogeneity and generally weak associations observed might be population differences (i.e. different mutations), differences in completeness of follow-up (often not reported), differences in consideration of contralateral breast cancer and prophylactic surgeries (usually not reported). Publication bias is unlikely to play a large role, as shown in our funnel plot; because of the low prevalence of *BRCA1/2* mutations in populations, also studies with only a small number of carriers were published.

The evidence-based conclusions drawn in our review are based on a tool, the best-evidence synthesis, which makes it possible to perform a standardized analysis of the available literature (tool developed by Monninkhof and colleagues \[[@pone.0120189.ref006]\], adapted by the authors for this review). The cut-offs for a relevant survival difference were arbitrarily chosen, but were defined a priori and were based on previous knowledge regarding breast cancer survival. In addition, the quality scores given to specific study aspects were developed with an expert group. The best-evidence synthesis only used the HQ studies (at least 50% of attainable quality score awarded); when performing the best-evidence synthesis using all studies ([Table 4](#pone.0120189.t004){ref-type="table"} and [Table 5](#pone.0120189.t005){ref-type="table"}) the results substantially changed, which indicates that HQ studies are indeed different from the other studies. This confirmed our idea that we took into account the most important sources of bias. Even so, it should be kept in mind that our scoring system is not a direct measure of validity and may not capture all methodological aspects adequately.

Two earlier published reviews also addressed the association between *BRCA1/2* carriership and breast cancer survival. Bordeleau and colleagues \[[@pone.0120189.ref064]\] included 25 studies and described the methodological problems of the studies per calendar period of publication. According to this review, the data provided reassurance that the overall prognosis of *BRCA*-associated breast cancer was similar to that of breast cancer not associated with *BRCA* mutations. For studies published in the 1990s they found several methodological limitations leading to inconclusive results. For more recently published studies they reported improved methodology but failure to demonstrate a significant overall survival difference. In our review we did not find a relation between the publication year and the quality of the studies (data not shown). The other review, published in 2010 by Lee and colleagues \[[@pone.0120189.ref065]\], included 17 studies and described methodological problems of these studies in the discussion section. They performed a meta-analysis on short-term (5-year) and long-term (10-year) overall and progression-free survival and based their final conclusions on the pooled estimate, although they stated that there was inconsistency in the results. Overall they concluded that *BRCA1* mutation carriership appears to decrease both short-term and long-term overall survival rates and short-term but not long-term progression-free survival. For *BRCA2* mutation carriers they observed no effect on either short-term or long-term survival. While these two reviews reached conflicting conclusions, they also differ from conclusions in our review, probably due to our more complete inclusion of papers and systematic way of analysing the results, as well as evaluation of the methodological aspects and the quality of the included studies.

On the basis of our systematic and evidence-based analysis of all studies published to date, we conclude that there is only moderate evidence for a worse recurrence-free survival for *BRCA1* mutation carriers, unadjusted for tumour characteristics. For all the other outcomes the evidence was judged to be indecisive, though if analysed in isolation, the 'unselected cohort studies' showed moderate evidence for a worse overall survival for *BRCA1* mutation carriers. Survival perspectives of *BRCA1/2* mutation carriers diagnosed with breast cancer are unclear and current evidence does not support differential treatment decisions (apart from the use of PARP inhibitors).

More high quality studies are needed that include a large number of incident breast cancer cases who are unselectively tested for *BRCA* mutations, with sufficient follow-up time, and information available on all patient and tumour characteristics, treatment and prophylactic surgeries. Our quality scoring system can help researchers when considering specific aspects of design and analysis which are important to reduce bias.
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